var title_f27_9_27792="Toxoplasma encephalitis MRI";
var content_f27_9_27792=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F74466&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F74466&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MRI scan of patient with Toxoplasma encephalitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 296px; height: 344px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple ring enhancing lesions with mass effect are visible after injection of gadolinium in this T1-weighted image.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_9_27792=[""].join("\n");
var outline_f27_9_27792=null;
var title_f27_9_27793="Glucose polymers: Drug information";
var content_f27_9_27793=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Glucose polymers: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F176532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Polycose&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F176536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Nutritional Supplement",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F176533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Caloric supplement:",
"     </b>",
"     Oral: Add the amount that will supply the desired number of additional calories to foods or beverages, or mix in water.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Caloric equivalents (U.S. household measures):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     One level teaspoon (2 g): 8 calories",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     One level tablespoon (6 g): 23 calories",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     One-fourth cup (25 g): 95 calories",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     One-third cup (33 g): 125 calories",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     One-half cup (50 g): 190 calories",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     One cup (100 g): 380 calories",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F176534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F176528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Polycose&reg;: 349 g",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F176522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F14386451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Wash your hands prior to use. May be administered orally or through a feeding tube.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixing with liquids: Pour the desired amount of water or beverage into an appropriate-sized container, and then stir in the powder with a spoon.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixing with foods: Mix directly into foods such as mashed potatoes, oatmeal, gravy, or soup.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F176529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Supplies calories for those persons not able to meet the caloric requirement with usual dietary intake",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F14386447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Not for I.V. use. Do not use as sole source of nutrition. Powder must be mixed with either liquid or food prior to administration.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8956 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-8D13A6BE0D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_9_27793=[""].join("\n");
var outline_f27_9_27793=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176532\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176536\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176533\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176534\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176528\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176522\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14386451\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176529\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14386447\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8956\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8956|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_9_27794="Contrast MDCT panc mass";
var content_f27_9_27794=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F56487&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F56487&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Contrast MDCT of pancreatic mass",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Contrast-enhanced MDCT in coronal projection demonstrates a small mass (yellow arrow) in the body of the pancreas, causing pancreatic ductal obstruction, with abrupt cutoff of the main pancreatic duct (white arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Rocio Perez-Johnston.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_9_27794=[""].join("\n");
var outline_f27_9_27794=null;
var title_f27_9_27795="Simethicone: Pediatric drug information";
var content_f27_9_27795=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Simethicone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?32/35/33332?source=see_link\">",
"    see \"Simethicone: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/43/5812?source=see_link\">",
"    see \"Simethicone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F221168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Equalizer Gas Relief [OTC];",
"     </li>",
"     <li>",
"      Gas Free Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Gas Relief Ultra Strength [OTC];",
"     </li>",
"     <li>",
"      Gas-X&reg; Children's Tongue Twisters&trade; [OTC];",
"     </li>",
"     <li>",
"      Gas-X&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Gas-X&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Gas-X&reg; Thin Strips&trade; [OTC];",
"     </li>",
"     <li>",
"      Gas-X&reg; [OTC];",
"     </li>",
"     <li>",
"      Gax-X&reg; Infant [OTC];",
"     </li>",
"     <li>",
"      Infantaire Gas [OTC];",
"     </li>",
"     <li>",
"      Infants Gas Relief Drops [OTC] [DSC];",
"     </li>",
"     <li>",
"      Little Tummys&reg; Gas Relief [OTC];",
"     </li>",
"     <li>",
"      Mi-Acid Gas Relief [OTC];",
"     </li>",
"     <li>",
"      Mylanta&reg; Gas Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Mylicon&reg; Infants' [OTC];",
"     </li>",
"     <li>",
"      Mytab Gas Maximum [OTC];",
"     </li>",
"     <li>",
"      Mytab Gas [OTC];",
"     </li>",
"     <li>",
"      Phazyme&reg; Ultra Strength [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F221169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ovol&reg;;",
"     </li>",
"     <li>",
"      Phazyme&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1062092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiflatulent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1062089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/35/33332?source=see_link\">",
"      see \"Simethicone: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children &lt;2 years: 20 mg 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 2-12 years: 40 mg 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;12 years and Adults: 40-250 mg after meals and at bedtime as needed, not to exceed 500 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F221159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral: 125 mg, 180 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gas Free Extra Strength: 125 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gas Relief Ultra Strength: 180 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gas-X&reg; Extra Strength: 125 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gas-X&reg; Maximum Strength: 166 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mylanta&reg; Gas Maximum Strength: 125 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phazyme&reg; Ultra Strength: 180 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Strip, orally disintegrating, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gas-X&reg; Children's Tongue Twisters&trade;: 40 mg (16s) [cinnamon flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gas-X&reg; Thin Strips&trade;: 62.5 mg (18s) [cinnamon flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gas-X&reg; Thin Strips&trade;: 62.5 mg (18s, 32s) [peppermint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral [drops]: 40 mg/0.6 mL (30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Equalizer Gas Relief: 40 mg/0.6 mL (30 mL) [contains sodium 0.15 mg/0.6 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gax-X&reg; Infant: 40 mg/0.6 mL (30 mL) [ethanol free; contains sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infantaire Gas: 40 mg/0.6 mL (30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants Gas Relief Drops: 40 mg/0.6 mL (30 mL [DSC]) [vanilla flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Little Tummys&reg; Gas Relief: 40 mg/0.6 mL (30 mL, 45 mL) [dye free, ethanol free; contains sodium benzoate; strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mylicon&reg; Infants': 40 mg/0.6 mL (15 mL, 30 mL) [dye free, ethanol free; contains sodium benzoate; non-staining formula]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mylicon&reg; Infants': 40 mg/0.6 mL (15 mL, 30 mL) [ethanol free; contains sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral: 80 mg, 125 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gas-X&reg;: 80 mg [scored; contains calcium 30 mg/tablet; cherry cr&egrave;me flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gas-X&reg;: 80 mg [contains calcium 30 mg/tablet; peppermint cr&egrave;me flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gas-X&reg; Extra Strength: 125 mg [contains calcium 45 mg/tablet; cherry cr&egrave;me flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gas-X&reg; Extra Strength: 125 mg [contains calcium 45 mg/tablet; peppermint cr&egrave;me flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mi-Acid Gas Relief: 80 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mylanta&reg; Gas Maximum Strength: 125 mg [scored; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mylanta&reg; Gas Maximum Strength: 125 mg [mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mytab Gas: 80 mg [peppermint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mytab Gas Maximum: 125 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F221147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes orally disintegrating strip",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1062096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer after meals or at bedtime; chew tablets thoroughly before swallowing; mix with water, infant formula or other liquid; place strips (Gas-X&reg; Children's Tongue Twisters&trade; or Gas-X&reg; Thin Strips&trade;) directly on the tongue",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1062095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relieve flatulence, functional gastric bloating, and postoperative gas pains",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F221183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Simethicone may be confused with cimetidine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Mylanta&reg; may be confused with Mynatal&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Mylicon&reg; may be confused with Modicon&reg;, Myleran&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F221182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gastrointestinal: Loose stools",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1062099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to simethicone or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1062088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Phazyme&reg; Quick Dissolve contains phenylalanine; avoid use or use with caution in phenylketonurics",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1062087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mylicon&reg; Infant drops contain sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites; avoid use of Mylicon&reg; Infant drops in neonates.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F221154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1062100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid gas-forming foods",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14186485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Simethicone is not absorbed systemically following oral administration. Systemic absorption would be required in order for simethicone to cross the placenta and reach the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1062086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Spreads on surface of aqueous liquids forming a film of low surface tension which collapses foam bubbles; allows mucous-surrounded gas bubbles to coalesce and be expelled",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1062098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Elimination: In feces",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1062091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/43/5812?source=see_link\">",
"      see \"Simethicone: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid carbonated beverages",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12791 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-961E418322-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_9_27795=[""].join("\n");
var outline_f27_9_27795=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221168\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221169\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062092\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062089\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221159\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221147\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062096\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062095\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221183\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221182\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062099\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062088\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062087\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300043\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221154\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062100\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14186485\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062086\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062098\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062091\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12791\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12791|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/35/33332?source=related_link\">",
"      Simethicone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/43/5812?source=related_link\">",
"      Simethicone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_9_27796="The epidemiology and clinical manifestations of murine typhus";
var content_f27_9_27796=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The epidemiology and clinical manifestations of murine typhus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/9/27796/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/9/27796/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/9/27796/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/9/27796/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/9/27796/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/9/27796/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/9/27796/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Murine (endemic) typhus is an uncommon flea-borne infectious disease caused by Rickettsia typhi. The illness is less commonly diagnosed in the United States than in the developing world because of improvements in hygiene and rat control efforts. The true incidence of this infection is difficult to establish because of the difficulty in distinguishing murine typhus from other causes of rash and fever.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rickettsia typhi is a member of the typhus group of rickettsiae that also includes the agent of epidemic typhus, R. prowazekii. These organisms are obligate intracellular, gram-negative bacteria that can only be grown in tissue culture, the cells of experimental animals, or chick embryos. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31364?source=see_link\">",
"     \"Biology of Rickettsia rickettsii infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Murine typhus is primarily transmitted by the rat flea, Xenopsylla cheopis. Additional vectors include the cat flea, Ctenocephalides felis, and the mouse flea, Leptopsyllia segnis. Fleas remain permanently infected with R. typhi, but their lifespan is not shortened by the presence of rickettsiae. Humans are infected by inoculation of infective flea feces in bite wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27796/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    House mice, cats, and shrews may occasionally serve as hosts to infected fleas, but the majority of cases of murine typhus are associated with sites in which rats accumulate in large numbers. However, in suburban locations in the United States, domestic cats, cat fleas, and opossums may maintain a suburban cycle of both R. typhi and R. felis, a spotted fever group rickettsia that is flea-borne and produces an illness that is clinically indistinguishable from murine typhus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27796/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28808?source=see_link\">",
"     \"Other spotted fever group rickettsial infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to serving as hosts for infected fleas, rats may become rickettsemic after contact with an infected flea and thereby transmit the organism to numerous other simultaneously feeding fleas. The resultant amplification of the infection may lead to rapid spread of infection among potential vectors.",
"   </p>",
"   <p>",
"    Murine typhus is not reported in surveillance data collected by most state health departments. In the United States, most cases of murine typhus have been recognized and reported in Texas, California, and Hawaii, although it is likely that the disease exists in a much wider geographic area. Murine typhus is likely underdiagnosed because it is easily mistaken for a viral illness, because patients are rarely aware of having had flea bites, and because many cases resolve spontaneously. A serological study of 513 children from south Texas showed that approximately 13 percent of children ages 1 to 17 had IgG antibodies reactive to R. typhi [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27796/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Murine typhus sporadically occurs on all the inhabited continents, in environments ranging from hot to cold and from humid to semi-arid [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27796/abstract/3\">",
"     3",
"    </a>",
"    ]. There is no seasonal variation in murine typhus in tropical areas, but in temperate regions the disease is most common in hot, dry periods, such as the late summer and early fall [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27796/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Outbreaks of murine typhus are uncommon. A report of a cluster of 53 cases of murine typhus in Austin, Texas suggested that a high density of infection in domestic animals or opossums may have been responsible for the hyperendemic foci of infection secondarily involving humans [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27796/abstract/4\">",
"     4",
"    </a>",
"    ]. Murine typhus is occasionally contracted by travelers who then return to the United States with clinical disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27796/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A limited number of autopsy studies of murine typhus cases have been performed due to the low case fatality rate [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27796/abstract/5\">",
"     5",
"    </a>",
"    ]. The primary pathological lesion of R. typhi infection is an inflammatory vasculitis characterized by perivascular infiltration of lymphocytes, macrophages, plasma, and mast cells. In rare cases, the vasculitis may be accompanied by mural or intimal thrombi in small vessels of the heart, lungs, kidneys, and central nervous system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Murine typhus is typically a mild illness with an incubation period from 8 to 16 days. The onset of illness is usually relatively abrupt, with nonspecific symptoms followed by fever and a rash.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Nonspecific symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever, headache, chills, and myalgias are usually prominent early in the illness. Nonspecific gastrointestinal symptoms such as nausea, vomiting, abdominal pain and diarrhea may also occur at this time. GI symptoms seem to be particularly common in children with murine typhus, occurring in 77 percent of 97 infected children in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27796/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Rash",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rash occurs in some patients near the end of the first week of illness. The frequency has ranged from 20 percent in a report from Thailand to 54 percent is a series from Texas [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27796/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The clinical triad of fever, headache, and rash was noted in only 49 percent of patients in the pediatric series cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27796/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rash of murine typhus typically begins as a maculopapular eruption on the trunk and spreads peripherally, sparing the palms and soles [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27796/abstract/1\">",
"     1",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_picture graphicRef67425 \" href=\"UTD.htm?13/48/14094\">",
"     picture 1",
"    </a>",
"    ). However, the pattern of evolution and distribution is sufficiently variable to preclude their use in differential diagnosis. The rash may be faint and difficult to see, particularly in dark-skinned individuals. In one study of 180 patients, for example, rash was observed in only 20 percent of black patients compared to 81 percent of white patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27796/abstract/9\">",
"     9",
"    </a>",
"    ]. The rash has a petechial component in less than 10 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27796/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the majority of patients experience mild illness, mental confusion and focal neurologic symptoms can rarely lead to diagnostic confusion. For example, one case report described a patient with murine typhus who developed facial paralysis and meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27796/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Signs and symptoms of hepatic, cardiac, renal, and pulmonary dysfunction can occur in severe cases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal dysfunction, which was present in one-fourth of cases in one review [",
"      <a class=\"abstract\" href=\"UTD.htm?27/9/27796/abstract/8\">",
"       8",
"      </a>",
"      ], can result from several mechanisms, including decreased renal perfusion (prerenal) and acute interstitial nephritis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/9/27796/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with more severe illness may develop cough and dyspnea. Chest radiographs in such patients may show interstitial infiltrates or changes suggestive of pulmonary edema [",
"      <a class=\"abstract\" href=\"UTD.htm?27/9/27796/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      As in other rickettsial diseases, ocular exam may show a variety of abnormalities ranging from exudates to hemorrhages to optic disk or vitreal inflammation. These changes are secondary to the widespread vasculitis that is the hallmark of this disease [",
"      <a class=\"abstract\" href=\"UTD.htm?27/9/27796/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Splenic rupture may rarely occur [",
"      <a class=\"abstract\" href=\"UTD.htm?27/9/27796/abstract/1,13,14\">",
"       1,13,14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As in other rickettsial diseases, the presence of glucose-6-phosphate dehydrogenase deficiency (G6PD) and advanced age appear to be host factors associated with severe or fatal disease. The association with G6PD was first described in a black American soldier who developed acute renal failure and severe hemolysis after contracting murine typhus in Vietnam [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27796/abstract/15\">",
"     15",
"    </a>",
"    ]. Several subsequent studies have shown an association between G6PD deficiency and severe or fulminant Rocky Mountain spotted fever (RMSF) and severe infection with the agent of boutonneuse fever (R. conorii) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27796/abstract/16\">",
"     16",
"    </a>",
"    ]. The mechanism of this association between severe rickettsial diseases and the presence of G6PD has never been conclusively established, but it has been proposed that G6PD-associated hemolysis may somehow aggravate or potentiate rickettsial vasculitides [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27796/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The routine laboratory findings in murine typhus are nonspecific. Thrombocytopenia is a common finding, occurring in 48 percent of patients in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27796/abstract/8\">",
"     8",
"    </a>",
"    ]. The white blood cell count is usually normal but mild leukocytosis or leukopenia can be seen. Hyponatremia and abnormal liver function tests occur in 60 and 90 percent of patients, respectively, although these abnormalities are usually mild [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27796/abstract/8\">",
"     8",
"    </a>",
"    ]. Cerebrospinal fluid abnormalities consistent with aseptic meningitis may occur in patients with murine typhus who undergo lumbar puncture [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27796/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8972644\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Murine (endemic) typhus is an uncommon flea-borne infectious disease caused by Rickettsia typhi. The illness is less commonly diagnosed in the United States than in the developing world because of improvements in hygiene and rat control efforts. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rickettsia typhi is a member of the typhus group of rickettsiae that also includes the agent of epidemic typhus, R. prowazekii. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Humans are infected by inoculation of infective flea feces within bite wounds. Murine typhus is primarily transmitted by the rat flea, Xenopsylla cheopis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Murine typhus is typically a mild illness with an incubation period from 8 to 16 days. The onset of illness is usually relatively abrupt, with nonspecific symptoms followed by fever and a maculopapular rash in 20 to 50 percent of patients. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Signs and symptoms of hepatic, cardiac, renal, and pulmonary dysfunction can occur in severe cases. As in other rickettsial diseases, the presence of glucose-6-phosphate dehydrogenase deficiency (G6PD) and advanced age appear to be associated with severe or fatal disease. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The routine laboratory findings in murine typhus are nonspecific. Thrombocytopenia is a common finding, occurring in approximately half of patients. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27796/abstract/1\">",
"      Civen R, Ngo V. Murine typhus: an unrecognized suburban vectorborne disease. Clin Infect Dis 2008; 46:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27796/abstract/2\">",
"      Purcell K, Fergie J, Richman K, Rocha L. Murine typhus in children, South Texas. Emerg Infect Dis 2007; 13:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27796/abstract/3\">",
"      Azad AF. Epidemiology of murine typhus. Annu Rev Entomol 1990; 35:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27796/abstract/4\">",
"      Centers for Disease Control and Prevention (CDC). Outbreak of Rickettsia typhi infection - Austin, Texas, 2008. MMWR Morb Mortal Wkly Rep 2009; 58:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27796/abstract/5\">",
"      Walker DH, Parks FM, Betz TG, et al. Histopathology and immunohistologic demonstration of the distribution of Rickettsia typhi in fatal murine typhus. Am J Clin Pathol 1989; 91:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27796/abstract/6\">",
"      Whiteford SF, Taylor JP, Dumler JS. Clinical, laboratory, and epidemiologic features of murine typhus in 97 Texas children. Arch Pediatr Adolesc Med 2001; 155:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27796/abstract/7\">",
"      Silpapojakul K, Chayakul P, Krisanapan S, Silpapojakul K. Murine typhus in Thailand: clinical features, diagnosis and treatment. Q J Med 1993; 86:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27796/abstract/8\">",
"      Dumler JS, Taylor JP, Walker DH. Clinical and laboratory features of murine typhus in south Texas, 1980 through 1987. JAMA 1991; 266:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27796/abstract/9\">",
"      Stuart, BM, Pullen, RL. Endemic (murine) typhus. Clinical observations of 180 cases. Ann Intern Med 1945; 23:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27796/abstract/10\">",
"      Vander T, Medvedovsky M, Valdman S, Herishanu Y. Facial paralysis and meningitis caused by Rickettsia typhi infection. Scand J Infect Dis 2003; 35:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27796/abstract/11\">",
"      Shaked Y, Shpilberg O, Samra Y. Involvement of the kidneys in Mediterranean spotted fever and murine typhus. Q J Med 1994; 87:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27796/abstract/12\">",
"      Khairallah M, Ben Yahia S, Toumi A, et al. Ocular manifestations associated with murine typhus. Br J Ophthalmol 2009; 93:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27796/abstract/13\">",
"      Fergie J, Purcell K. Spontaneous splenic rupture in a child with murine typhus. Pediatr Infect Dis J 2004; 23:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27796/abstract/14\">",
"      McKelvey SD, Braidly PC, Stansby GP, Weir WR. Spontaneous splenic rupture associated with murine typhus. J Infect 1991; 22:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27796/abstract/15\">",
"      Whelton A, Donadio JV Jr, Elisberg BL. Acute renal failure complicating rickettsial infections in glucose-6-phosphate dehydrogenase-deficient individuals. Ann Intern Med 1968; 69:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27796/abstract/16\">",
"      Walker DH. The role of host factors in the severity of spotted fever and typhus rickettsioses. Ann N Y Acad Sci 1990; 590:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27796/abstract/17\">",
"      Walker DH. Rocky Mountain spotted fever: a seasonal alert. Clin Infect Dis 1995; 20:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27796/abstract/18\">",
"      Masalha, R, Merkin-Zaborsky, H, Matar, M. Murine typhus presenting as subacute meningoencephalitis. J Neurol 1998; 22:296.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7906 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-110.124.11.8-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_9_27796=[""].join("\n");
var outline_f27_9_27796=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8972644\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGEN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Nonspecific symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Rash",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8972644\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7906\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7906|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/48/14094\" title=\"picture 1\">",
"      Murine typhus rash",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31364?source=related_link\">",
"      Biology of Rickettsia rickettsii infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28808?source=related_link\">",
"      Other spotted fever group rickettsial infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_9_27797="Moexipril and hydrochlorothiazide: Patient drug information";
var content_f27_9_27797=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Moexipril and hydrochlorothiazide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16791?source=see_link\">",
"     see \"Moexipril and hydrochlorothiazide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F198337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Uniretic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F198338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Uniretic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10030731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use during pregnancy may cause birth defects or loss of the unborn baby. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702545",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to moexipril, hydrochlorothiazide, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703370",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: A block in the kidneys' arteries or other kidney disease; hyperaldosteronism; or swelling in the face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3915366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes) and are taking aliskiren.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), this drug may sometimes raise blood sugar. Talk with your doctor about how to fine tune this.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Watch for gout attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698359",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sunburn.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have too much sweat, fluid loss, throwing up, or loose stools. This may lead to low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause you to pass urine more often. To keep from having sleep problems, try to take before 6 pm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10875 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-9CEA1CDAAA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_9_27797=[""].join("\n");
var outline_f27_9_27797=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198337\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198338\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030731\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030733\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030732\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030737\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030738\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030740\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030735\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030736\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030741\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030742\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16791?source=related_link\">",
"      Moexipril and hydrochlorothiazide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_9_27798="Ectopic ureter male";
var content_f27_9_27798=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    Location of ectopic ureteral orifices in boys",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 586px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Possible sites for ectopic ureter insertion are shown. The green dotted line demonstrates other potential sites for ectopic ureters in males, all of which are proximal to the external urethral sphincter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_9_27798=[""].join("\n");
var outline_f27_9_27798=null;
var title_f27_9_27799="Dexlansoprazole: Drug information";
var content_f27_9_27799=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dexlansoprazole: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/27/2485?source=see_link\">",
"    see \"Dexlansoprazole: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F16572475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Bone Fracture Risk with Proton Pump Inhibitors: Health Canada Issues Alert",
"     </span>",
"     <span class=\"collapsible-date\">",
"      April 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Health Canada has informed healthcare professionals that proton pump inhibitors (PPIs) may increase the risk of bone fractures. The risk of fracture was observed to be higher in patients receiving multiple daily doses for &ge;1 year; age, gender, and concomitant health conditions may also be a factor. Patients with risk factors for osteoporosis should be closely monitored and should receive a PPI at the lowest effective dose and for the shortest duration of therapy appropriate for the condition.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For more information, refer to file://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/26523a-eng.php.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6884085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dexilant&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F10526786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dexilant&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F6892890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Proton Pump Inhibitor;",
"     </li>",
"     <li>",
"      Substituted Benzimidazole",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F6892955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Erosive esophagitis (EE):",
"     </b>",
"     Oral: Short-term treatment: 60 mg once daily for up to 8 weeks; maintenance of healed EE and symptomatic relief of heartburn: 30 mg once daily for up to 6 months.",
"     <b>",
"      Note:",
"     </b>",
"     Doses &gt;30 mg do not provide additional benefit during maintenance phase.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Symptomatic GERD:",
"     </b>",
"     Oral: Short-term treatment: 30 mg once daily for 4 weeks.",
"     <b>",
"      Note:",
"     </b>",
"     Doses &gt;30 mg do not provide additional benefit during maintenance phase.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F6892956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F6892957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F6892958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild hepatic impairment (Child-Pugh class A): No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate hepatic impairment (Child-Pugh class B): Consider a maximum dose of 30 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe hepatic impairment (Child-Pugh class C): No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F6892969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, delayed release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dexilant&trade;: 30 mg, 60 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F6892888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F15241699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM322208.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM322208.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6892966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals; some patients may benefit from premeal administration if symptoms do not adequately respond to post-meal dosing. Capsules should be swallowed whole; alternatively, patients who are unable to swallow capsules may open the capsule, sprinkle the intact granules onto 1 tablespoon of applesauce, and swallow intact granules immediately.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F6892892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term (4 weeks) treatment of heartburn associated with nonerosive GERD; short-term (up to 8 weeks) treatment of all grades of erosive esophagitis (EE); to maintain healing of erosive esophagitis and relief of heartburn for up to 6 months",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6892886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Dexlansoprazole may be confused with aripiprazole, lansoprazole",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Kapidex [DSC] may be confused with Casodex&reg;, Kadian&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Kapidex [DSC] may be confused with Capadex which is a brand name for propoxyphene/acetaminophen combination product [Australia, New Zealand]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F6892916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (5%), abdominal pain (4%), nausea (3%), flatulence (1% to 3%), vomiting (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory tract infection (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;2% (Limited to important or life-threatening): Abdominal discomfort/tenderness, abnormal dreams/feelings, abnormal taste, acne, acute renal failure, alkaline phosphatase increased, ALT increased, anal discomfort, anaphylaxis, anemia, angina, anxiety, arrhythmia, arthralgia, arthritis, aspiration, AST increased, asthma, autoimmune hemolytic anemia, Barrett&rsquo;s esophagus, bezoar, bilirubin increased/decreased, blurred vision, bowel sounds abnormal, bradycardia, breath odor, bronchitis, cerebrovascular accident, chest pain, chills, cholecystitis (acute), cholelithiasis,",
"     <i>",
"      Clostridium difficile",
"     </i>",
"     -associated diarrhea (CDAD), colic (biliary), colitis (microscopic), colonic polyp, constipation, cough, creatinine increased, deafness,  depression, dermatitis, diabetes mellitus, dizziness, duodenitis, DVT, dysmenorrhea, dyspareunia, dyspepsia, dysphagia, dysphonia, dyspnea, dysuria, ear pain, edema (including oral, facial, and pharyngeal), enteritis, eructation, erythema, esophagitis, eye irritation, eye swelling, feces abnormal, fever, fracture, gastric polyp, gastritis, gastroenteritis, gastrointestinal perforation, gastrointestinal ulceration, GI hypermotility, goiter, hallucinations (auditory), headache, hematemesis, hematochezia, hemorrhoids, hepatitis, hepatomegaly, hiccups, hot flashes, hypercalcemia, hyperglycemia, hyper-/hypokalemia, hyperlipidemia, hypersensitivity, hypertension, hyperventilation, hypomagnesemia, hyponatremia, hypothyroidism, impaired gastric emptying, infections (",
"     <i>",
"      Candida",
"     </i>",
"     , herpes, influenza, vaginal, viral), inflammation (mucosal), insomnia, irritable bowel syndrome, ITP, joint sprains, leukocytoclastic vasculitis, libido changes, lymphadenopathy, memory impairment, menorrhagia, migraine, mucous stools, myalgia, MI, nasopharyngitis, neutropenia, nodule, oral mucosal blistering, osteoporosis-related fracture, pain, painful defecation, palpitation, pancreatitis, paresthesia, pharyngitis, pneumonia, proctitis, pruritus, psychomotor hyperactivity, rash, rectal bleeding, seizure, sinusitis, skin lesion, Stevens-Johnson syndrome, sunburn, tachycardia, throat tightness, thrombocytopenia, tinnitus, toxic epidermal necrolysis, transient ischemic attack, tremor, urinary urgency, urticaria, vertigo, weakness, weight gain, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F6892897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dexlansoprazole or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6892898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Atrophic gastritis: Long-term omeprazole therapy has caused atrophic gastritis (by biopsy); this may also occur with dexlansoprazole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carcinoma: No occurrences of enterochromaffin-like (ECL) cell carcinoids, dysplasia, or neoplasia, such as those seen in rodent studies, have been reported in humans.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;",
"     <i>",
"      Clostridium difficile",
"     </i>",
"     -associated diarrhea (CDAD): Use of proton pump inhibitors (PPIs) may increase risk of CDAD, especially in hospitalized patients; consider CDAD diagnosis in patients with persistent diarrhea that does not improve. Use the lowest dose and shortest duration of PPI therapy appropriate for the condition being treated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fractures: Increased incidence of osteoporosis-related bone fractures of the hip, spine, or wrist may occur with proton pump inhibitor (PPI) therapy. Patients on high-dose (multiple daily doses) or long-term therapy (&ge;1 year) should be monitored. Use the lowest effective dose for the shortest duration of time, use vitamin D and calcium supplementation, and follow appropriate guidelines to reduce risk of fractures in patients at risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypomagnesemia: Reported rarely, usually with prolonged PPI use of &gt;3 months (most cases &gt;1 year of therapy). May be symptomatic or asymptomatic; severe cases may cause tetany, seizures, and cardiac arrhythmias. Consider obtaining serum magnesium concentrations prior to beginning long-term therapy, especially if taking concomitant digoxin, diuretics, or other drugs known to cause hypomagnesemia; and periodically thereafter.  Hypomagnesemia may be corrected by magnesium supplementation, although discontinuation of dexlansoprazole may be necessary; magnesium levels typically return to normal within 1 week of stopping.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastric malignancy: Relief of symptoms does not preclude the presence of a gastric malignancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal infection (eg,",
"     <i>",
"      Salmonella, Campylobacter",
"     </i>",
"     ): Use of proton pump inhibitors may increase risk of these infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Patients with moderate hepatic impairment (Child-Pugh class B) may require dosage reductions; no studies have been conducted in patients with severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends either avoidance of both omeprazole (even when scheduled 12 hours apart) and esomeprazole or use of a PPI with comparatively less effect on the active metabolite of clopidogrel (eg, pantoprazole). Although lansoprazole exhibits the most potent CYP2C19 inhibition",
"     <i>",
"      in vitro",
"     </i>",
"     (Li, 2004; Ogilvie, 2011), an",
"     <i>",
"      in vivo",
"     </i>",
"     study of extensive CYP2C19 metabolizers showed less reduction of the active metabolite of clopidogrel when administered with lansoprazole/dexlansoprazole compared to esomeprazole/omeprazole (Frelinger, 2012).  The  manufacturer of dexlansoprazole states that no dosage adjustment is necessary for clopidogrel when used concurrently with approved doses.  In contrast to these warnings, others have recommended the continued use of PPIs, regardless of the degree of inhibition, in patients with a history of GI bleeding or multiple risk factors for GI bleeding who are also receiving clopidogrel since no evidence has established clinically meaningful differences in outcome; however, a clinically-significant interaction cannot be excluded in those who are poor metabolizers of clopidogrel (Abraham, 2010; Levine, 2011).The  manufacturer of dexlansoprazole states that no dosage adjustment is necessary for clopidogrel when used concurrently with approved doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for other interactions: Concomitant use of dexlansoprazole with some drugs may require cautious use, may not be recommended, or may require dosage adjustments.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F7278224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F7278223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Proton Pump Inhibitors may increase the serum concentration of Amphetamines. Specifically, data indicate that Proton Pump Inhibitors may increase the rate at which Amphetamines are absorbed.  Total exposure to Amphetamines is not significantly changed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Proton Pump Inhibitors may decrease the serum concentration of Atazanavir.  Management: Avoid concurrent PPI in HIV treatment-experienced patients.  For treatment-naive patients, atazanavir/ritonavir dose should be given approximately 12 hours after the PPI, and the PPI should not exceed the equivalent of 20 mg omeprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Proton Pump Inhibitors may increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Proton Pump Inhibitors may diminish the therapeutic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: Proton Pump Inhibitors may decrease the serum concentration of Bosutinib.  Management: Consider alternatives to proton pump inhibitors, such as antacids or H2 receptor antagonists.  Administer alternative agents more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: Proton Pump Inhibitors may decrease the serum concentration of Cefditoren.  Management: If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Dexlansoprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel.  Management: Due to the possible risk for impaired clopidogrel effectiveness, clinicians should carefully consider the need for proton pump inhibitor therapy in patients receiving clopidogrel.  Other acid-lowering therapies do not appear to share this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Dabigatran Etexilate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Proton Pump Inhibitors may decrease the serum concentration of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of the proton pump inhibitor if some acid-reducing therapy is needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: Proton Pump Inhibitors may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with proton pump inhibitors (PPIs) should be avoided in patients treated with delavirdine.  The clinical significance of short-term PPI therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: Proton Pump Inhibitors may increase the absorption of Dexmethylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Proton Pump Inhibitors may decrease the serum concentration of Erlotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Proton Pump Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: Proton Pump Inhibitors may decrease the serum concentration of Gefitinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: Proton Pump Inhibitors may decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: Proton Pump Inhibitors may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Proton Pump Inhibitors may decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Proton Pump Inhibitors may decrease the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Proton Pump Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: Proton Pump Inhibitors may diminish the therapeutic effect of Mesalamine. Proton pump inhibitor-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Consider avoiding concurrent administration of high-dose proton pump inhibitors (PPIs) with sustained-release mesalamine products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Proton Pump Inhibitors may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Proton Pump Inhibitors may increase the absorption of Methylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Proton Pump Inhibitors may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Proton Pump Inhibitors may decrease the serum concentration of Mycophenolate. Specifically, concentrations of the active mycophenolic acid may be reduced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Nelfinavir. Proton Pump Inhibitors may decrease the serum concentration of Nelfinavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: Proton Pump Inhibitors may decrease the serum concentration of Nilotinib.  Management: Avoid this combination when possible since separation of doses is not likely to be an adequate method of minimizing the interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: Proton Pump Inhibitors may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: Proton Pump Inhibitors may decrease the serum concentration of Posaconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raltegravir: Proton Pump Inhibitors may increase the serum concentration of Raltegravir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Proton Pump Inhibitors may decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Risedronate: Proton Pump Inhibitors may diminish the therapeutic effect of Risedronate. Proton Pump Inhibitors may increase the serum concentration of Risedronate. This applies specifically to use of delayed-release risedronate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: Proton Pump Inhibitors may increase the serum concentration of Saquinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Proton Pump Inhibitors may increase the serum concentration of Tacrolimus (Systemic).  Management: Tacrolimus dose adjustment may be required. Rabeprazole, pantoprazole, or selected H2-receptor antagonists (i.e., ranitidine or famotidine) may be less likely to interact. Genetic testing may predict patients at highest risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May decrease the serum concentration of Proton Pump Inhibitors. These data are derived from studies with Ritonavir-boosted Tipranavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: Proton Pump Inhibitors may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: Proton Pump Inhibitors may increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Proton Pump Inhibitors.  Management: In patients receiving omeprazole 40 mg/day or greater, reduce omeprazole dose by half when initiating voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F6892920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Ethanol: Avoid ethanol (may cause gastric mucosal irritation).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F6892893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6892894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have not shown teratogenic effects to the fetus. However, there are no adequate and well-controlled studies in pregnant women; use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6892896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F6892965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals; some patients may benefit from premeal administration if symptoms do not adequately respond to post-meal dosing.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, delayed release",
"     </b>",
"     (Dexilant Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (30): $170.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (30): $170.56",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F6892943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Proton pump inhibitor; decreases acid secretion in gastric parietal cells through inhibition of (H+, K+)-ATPase enzyme system, blocking the final step in gastric acid production",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F6892945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 40.3 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~96% to 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic via CYP2C19-mediated hydroxylation and CYP3A4-mediated oxidation; followed by reduction to sulfate, glucuronide, and glutathione conjugates (inactive)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: May be increased when administered with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life, elimination: ~1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, serum:",
"     <b>",
"      Note:",
"     </b>",
"     Two distinct peaks secondary to dual release formulation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Peak 1: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Peak 2: 4-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (~51% as metabolites); feces (~48% as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abraham NS, Hlatky MA, Antman EM, et al, &ldquo;ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(24):2619-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/9/27799/abstract-text/21060077/pubmed\" id=\"21060077\" target=\"_blank\">",
"        21060077",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bell AD, Roussin A, Cartier R, et al, &ldquo;The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2011, 27(Suppl A):1-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/9/27799/abstract-text/21640290/pubmed\" id=\"21640290\" target=\"_blank\">",
"        21640290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Jager CP, Wever PC, Gemen EF, et al, &ldquo;Proton Pump Inhibitor Therapy Predisposes to Community-Acquired",
"      <i>",
"       Streptococcus pneumoniae",
"      </i>",
"      Pneumonia,&rdquo;",
"      <i>",
"       Aliment Pharmacol Ther",
"      </i>",
"      , 2012, 36(10):941-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/9/27799/abstract-text/23034135/pubmed\" id=\"23034135\" target=\"_blank\">",
"        23034135",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/9/27799/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeVault KR and Castell DO, &ldquo;Updated Guidelines for the Diagnosis and Treatment of Gastroesophageal Reflux Disease,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2005, 100(1):190-200.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/9/27799/abstract-text/15654800/pubmed\" id=\"15654800\" target=\"_blank\">",
"        15654800",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frelinger AL 3rd, Lee RD, Mulford DJ, et al, &ldquo;A Randomized, 2-Period, Crossover Design Study to Assess the Effects of Dexlansoprazole, Lansoprazole, Esomeprazole, and Omeprazole on the Steady-State Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Volunteers,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2012, 59(14):1304-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/9/27799/abstract-text/22464259/pubmed\" id=\"22464259\" target=\"_blank\">",
"        22464259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kahrilas PJ, Shaheen NJ, Vaezi MF, et al, &ldquo;American Gastroenterological Association Medical Position Statement on the Management of Gastroesophageal Reflux Disease,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2008, 135(4):1383-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/9/27799/abstract-text/18789939/pubmed\" id=\"18789939\" target=\"_blank\">",
"        18789939",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lanza FL, Chan FK, and Quigley EM, &ldquo;Guidelines for Prevention of NSAID-Related Ulcer Complications,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2009, 140(3):728-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/9/27799/abstract-text/19240698/pubmed\" id=\"19240698\" target=\"_blank\">",
"        19240698",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):e574-651.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/9/27799/abstract-text/22064601/pubmed\" id=\"22064601\" target=\"_blank\">",
"        22064601",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Li XQ, Andersson TB, Ahalstr&ouml;m M, et al, \"Comparison of Inhibitory Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole and Rabeprazole on Human Cytochrome P450 Activities,\"",
"      <i>",
"       Drug Metab Dispo",
"      </i>",
"      , 2004, 32(8):821-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/9/27799/abstract-text/15258107/pubmed\" id=\"15258107\" target=\"_blank\">",
"        15258107",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ogilvie BW, Yerino P, Kazmi F, et al, &ldquo;The Proton Pump Inhibitor, Omeprazole, but not Lansoprazole or Pantoprazole, is a Metabolism-Dependent Inhibitor of CYP2C19: Implications for Coadministration With Clopidogrel,&rdquo;",
"      <i>",
"       Drug Metab Dispos",
"      </i>",
"      , 2011, 39(11):2020-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/9/27799/abstract-text/21795468/pubmed\" id=\"21795468\" target=\"_blank\">",
"        21795468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sharma P, Shaheen NJ, Perez MC, et al, &ldquo;Healing of Erosive Oesophagitis With TAK-390MR, a Proton Pump Inhibitor With a Novel Dual Delayed-Release Formulation: Results From Two Randomized Controlled Studies,&rdquo;",
"      <i>",
"       Aliment Pharmacol Ther",
"      </i>",
"      , 2009, 29(7):731-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/9/27799/abstract-text/19183157/pubmed\" id=\"19183157\" target=\"_blank\">",
"        19183157",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Talley NJ and Vakil N, &ldquo;Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the Management of Dyspepsia,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2005, 100(10):2324-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/9/27799/abstract-text/16181387/pubmed\" id=\"16181387\" target=\"_blank\">",
"        16181387",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wolfe MM and Sachs G, &ldquo;Acid Suppression: Optimizing Therapy for Gastroduodenal Ulcer Healing, Gastroesophageal Reflux Disease, and Stress-Related Erosive Syndrome,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2000,118(2 Suppl 1):9-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/9/27799/abstract-text/10868896/pubmed\" id=\"10868896\" target=\"_blank\">",
"        10868896",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9074 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-4C9EBFD82E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_9_27799=[""].join("\n");
var outline_f27_9_27799=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16572475\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6884085\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10526786\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6892890\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6892955\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6892956\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6892957\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6892958\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6892969\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6892888\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15241699\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6892966\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6892892\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6892886\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6892916\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6892897\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6892898\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7278224\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7278223\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6892920\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6892893\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6892894\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6892896\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6892965\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321921\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6892943\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6892945\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9074\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9074|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/27/2485?source=related_link\">",
"      Dexlansoprazole: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_9_27800="Bronchiolitis obliterans Light";
var content_f27_9_27800=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54489&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54489&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bronchiolitis obliterans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 333px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph showing a polypoid mass of granulation tissue protruding into the bronchiolar lumen and attached to an area where the mucosa is ulcerated. There is fibrotic thickening of the bronchiolar wall.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E King, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_9_27800=[""].join("\n");
var outline_f27_9_27800=null;
var title_f27_9_27801="Tinea versicolor back";
var content_f27_9_27801=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72396%7EPC%2F73839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72396%7EPC%2F73839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tinea versicolor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 397px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tinea versicolor. Hypopigmented macules and patches are present on the back.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Berg D, Worzala K. Atlas of Adult Physical Diagnosis, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tinea versicolor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 281px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tinea versicolor. Hypopigmented macules and patches are scattered on the shoulder and arm of this patient.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_9_27801=[""].join("\n");
var outline_f27_9_27801=null;
var title_f27_9_27802="Bipolar disorder in adults: Maintenance treatment";
var content_f27_9_27802=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bipolar disorder in adults: Maintenance treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/9/27802/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/9/27802/contributors\">",
"     Robert M Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/9/27802/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/9/27802/contributors\">",
"     Paul Keck, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/9/27802/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/9/27802/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/9/27802/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following remission of a bipolar mood episode, patients generally require maintenance treatment to delay or prevent another episode. Standard maintenance treatment consists of pharmacotherapy plus adjunctive psychotherapy. However, if psychotherapy is not available or is declined, pharmacotherapy alone is reasonable.",
"   </p>",
"   <p>",
"    Maintenance treatment for bipolar disorder is reviewed here. The pharmacotherapy of acute bipolar mood episodes; teratogenic risks and neonatal issues involved in pharmacotherapy; and the epidemiology, clinical manifestations, and diagnosis of bipolar disorder are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38026?source=see_link\">",
"       \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/3/44088?source=see_link\">",
"       \"Bipolar disorder in adults: Pharmacotherapy for acute depression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11226?source=see_link\">",
"       \"Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=see_link\">",
"       \"Bipolar disorder in adults: Epidemiology and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapses occur in most patients with bipolar disease and can be life-threatening. Thus, multiple treatment guidelines recommend maintenance pharmacotherapy for every patient [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The goals for maintenance therapy are to reduce residual symptoms, delay and prevent recurrence of new mood episodes, reduce the risk of suicide, and enhance psychosocial functioning.",
"   </p>",
"   <p>",
"    Bipolar disorder is typically a recurrent illness. As an example, the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) followed 858 patients who recovered from a mood episode, and found that nearly 50 percent subsequently had a recurrent episode within two years, despite receiving treatment at a specialty mood disorder clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/4\">",
"     4",
"    </a>",
"    ]. Another study of 172 patients with bipolar I disorder reported an 85 percent relapse rate over five years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrence of bipolar mood episodes is associated with a greater number of suicide attempts [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. This may be minimized by maintenance therapy; an observational study of 406 patients followed for up to 22 years found that bipolar patients who received maintenance treatment had lower rates of suicide deaths compared to those not treated (standardized mortality ratio 6 versus 27) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrences are harmful in other ways. Recurrent episodes are associated with poorer social and occupational functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition, cognitive impairment in euthymic patients is correlated with the number of prior mood episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/13\">",
"     13",
"    </a>",
"    ]. Each mood episode appears to increase the risk of treatment resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], perhaps because a recurrent mood episode may not remit as readily as the prior episode. For patients who successfully respond to maintenance treatment, treatment resistance may be minimized and the overall cost of therapy may be reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although most maintenance treatment studies have primarily or exclusively enrolled patients with bipolar I disorder, we suggest maintenance treatment for bipolar II disorder as well. Patients with bipolar II disorder are symptomatically ill more than 50 percent of their lives following onset of the illness and are at high risk for suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/1,17\">",
"     1,17",
"    </a>",
"    ]. In addition, some patients diagnosed with bipolar II disorder actually have bipolar I disorder, but have yet to suffer their first episode of mania. Multiple treatment guidelines recommend maintenance treatment for bipolar II disorder despite the lack of evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We also suggest maintenance treatment for bipolar disorder not otherwise specified, based upon our clinical experience. Although there are no controlled trials or observational studies to guide management [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/3,18\">",
"     3,18",
"    </a>",
"    ], the disorder is nevertheless a clinically significant syndrome that requires acute and maintenance treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259506221\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The three types of bipolar disorder defined in the American Psychiatric Association&rsquo;s Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision are [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bipolar I",
"     </li>",
"     <li>",
"      Bipolar II",
"     </li>",
"     <li>",
"      Bipolar disorder not otherwise specified (NOS)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional information about the diagnosis of bipolar disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=see_link&amp;anchor=H4#H4\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\", section on 'Clinical manifestations and diagnostic criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHARMACOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance pharmacotherapy usually consists of the same regimen that successfully treated the acute bipolar mood episode [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/3,22\">",
"     3,22",
"    </a>",
"    ]. This was evaluated in two studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial of 148 acutely manic patients who initially remitted with open-label divalproex (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      ) and were then assigned to maintenance treatment with divalproex,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , or placebo, time to recurrence was significantly longer with divalproex compared with lithium or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/23\">",
"       23",
"      </a>",
"      ]. This result, in conjunction with other findings that demonstrate lithium is an efficacious maintenance treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/24-26\">",
"       24-26",
"      </a>",
"      ], supports maintaining successful acute phase medications rather than switching.",
"     </li>",
"     <li>",
"      In a randomized trial in which 1172 patients with a manic, depressive, or mixed episode were initially stabilized with open-label",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      and then assigned to maintenance quetiapine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , or placebo, time to recurrence was significantly longer with quetiapine compared to lithium or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/27\">",
"       27",
"      </a>",
"      ]. &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Certain drugs may be more effective in treating one pole of the illness than the other pole. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38026?source=see_link\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/3/44088?source=see_link\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinicians should initially attempt to manage patients with monotherapy to enhance compliance and minimize side effects and costs. However, many bipolar patients require medication combinations for acute and maintenance treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Medication combinations'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38026?source=see_link&amp;anchor=H7954915#H7954915\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\", section on 'Severe manic and mixed episodes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     First line",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following first-line medications are consistently supported across multiple randomized trials, and are presented in our general order of preference based upon the number of trials conducted, risk of side effects, and cost:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       Lamotrigine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"       Risperidone",
"      </a>",
"      intramuscular injection for nonadherent patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Lithium",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    has been more widely studied than any other maintenance treatment for bipolar disorder. Evidence for the efficacy of maintenance lithium treatment includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of five randomized trials (753 patients with bipolar disorder) found relapses occurred in significantly fewer patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      compared with placebo (41 versus 61 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/25\">",
"       25",
"      </a>",
"      ]. A prior meta-analysis yielded essentially the same results [",
"      <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/26\">",
"       26",
"      </a>",
"      ]. Lithium appeared especially effective in preventing manic recurrences.",
"     </li>",
"     <li>",
"      A subsequent two-year randomized maintenance trial found that time to recurrence of mania or depression were each significantly longer in patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      than placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A subsequent open-label, two-year, randomized maintenance trial (Bipolar Affective disorder:",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"        Lithium",
"       </a>",
"       /Anticonvulsant",
"      </span>",
"      Evaluation; BALANCE) compared lithium monotherapy,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      monotherapy, or lithium plus valproate in 330 patients initially stabilized with the combination [",
"      <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/24\">",
"       24",
"      </a>",
"      ]. Recurrence was reduced for patients who received lithium monotherapy (hazard ratio 0.71, 95% CI 0.51-1.00) or the combination (hazard ratio 0.59, 95% CI 0.42-0.83), compared with valproate monotherapy. There was no significant difference between lithium monotherapy compared with the combination. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The initial dose is 300 mg two to three times per day. It is then titrated to achieve a target 12-hour serum trough level of 0.8 to 1.2",
"    <span class=\"nowrap\">",
"     mEq/L,",
"    </span>",
"    and taken once or twice per day. The serum level can be reduced to 0.6",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    (or lower if necessary) for patients unable to tolerate higher levels. Common side effects include weight gain, tremor, gastrointestinal distress, impaired ability to concentrate urine, polyuria, and hypothyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/3/43065?source=see_link\">",
"     \"Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259506193\">",
"    <span class=\"h4\">",
"     Reduced risk of suicide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    also appears to reduce the risk of suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/28\">",
"     28",
"    </a>",
"    ]. A meta-analysis of randomized trials and observational studies found a 13-fold decrease in annual rates of attempted or completed suicide for bipolar patients receiving lithium treatment compared with patients not receiving lithium (0.2 versus 2.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition, observational studies of health plans and a nationwide medical registry found significantly reduced rates of suicide attempts and suicide deaths associated with use of lithium [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Lamotrigine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of three randomized maintenance trials found",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    reduced the risk of relapse by 16 percent compared with placebo (risk ratio 0.84, 95% CI 0.71-0.99) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/25\">",
"     25",
"    </a>",
"    ]. Lamotrigine appeared more effective in delaying or preventing depression than manic or mixed episodes.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     Lamotrigine",
"    </a>",
"    is typically started at a dose of 25 mg per day for weeks one and two. For weeks three and four, the dose is increased to 50 mg per day, taken in two divided doses. The dose can then be titrated up by 25 to 50 mg per day, one week at a time for each increase. This slow titration reduces the risk of serious and life-threatening skin rash. The target dose generally ranges from 50 to 200 mg per day, taken in two divided doses; however, doses up to 400 mg per day may be required. An extended release formulation is also available for once a day dosing. Common side effects include nausea, dyspepsia, pain, insomnia, and nonserious skin rash.",
"   </p>",
"   <p>",
"    If the dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    is slowly escalated, it rarely causes a serious rash, defined as any rash associated with hospitalization, discontinuation of lamotrigine, or Stevens-Johnson syndrome (toxic epidermal necrolysis). In four acute and four maintenance randomized trials that included 1792 bipolar patients treated with lamotrigine, no cases of serious rash occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/32\">",
"     32",
"    </a>",
"    ]. In an additional 480 bipolar patients treated in uncontrolled trials, there were three cases. Thus, the total incidence of serious rash in 2272 patients was 0.1 percent.",
"   </p>",
"   <p>",
"    Additional information about the pharmacology of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=see_link&amp;anchor=H5#H5\">",
"     \"Pharmacology of antiepileptic drugs\", section on 'Lamotrigine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H170721048\">",
"    <span class=\"h3\">",
"     Risperidone intramuscular injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acutely ill patients stabilized with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    can be maintained with intramuscular injections of long-acting risperidone. Many patients refuse this option because they dislike receiving injections, and most authorities and clinicians reserve this treatment for bipolar I patients who do not adhere to treatment with oral medication. Adherence is discussed separately. (See",
"    <a class=\"local\" href=\"#H1205113\">",
"     'Adherence'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Two randomized maintenance trials (799 total patients), lasting two years, both demonstrated the efficacy of long-acting injectable",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/33\">",
"     33",
"    </a>",
"    ]. As an example, one trial found that relapse occurred in significantly fewer patients who received risperidone compared with placebo (30 versus 56 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/34\">",
"     34",
"    </a>",
"    ]. Risperidone appeared more efficacious in delaying or preventing mania than major depression. No trials have evaluated oral risperidone for maintenance treatment of bipolar disorder.",
"   </p>",
"   <p>",
"    The usual starting dose of long-acting injectable",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    is 25 mg every two weeks, but patients with a lower body mass index or sensitivity to side effects may benefit from an initial dose of 12.5 mg. After the first injection, oral risperidone is continued for three weeks (then discontinued) to maintain adequate therapeutic plasma concentrations prior to the main release phase of risperidone from the injection site. The dose of long-acting injectable risperidone can be increased to 37.5 or 50 mg every two weeks in patients with a larger body mass index or persistent or recurrent symptoms; a minimum of four weeks should elapse between dose adjustments. In addition, patients may benefit from intermittent use of oral risperidone to treat subsyndromal symptoms that occur during maintenance treatment with long-acting injectable risperidone.",
"   </p>",
"   <p>",
"    Additional information about the pharmacology of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link&amp;anchor=H76524679#H76524679\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\", section on 'Risperidone'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Second line",
"    </span>",
"    &nbsp;&mdash;&nbsp;We consider these medications second-line maintenance treatment because the evidence supporting their use is not as extensive or consistent compared with first-line drugs, or tolerability is poorer:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"       Aripiprazole",
"      </a>",
"     </li>",
"     <li>",
"      Divalproex",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       Quetiapine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       Olanzapine",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Aripiprazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three randomized trials evaluated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    as maintenance treatment, and two found that it was efficacious [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/35\">",
"     35",
"    </a>",
"    ]. A 100-week trial with 161 patients found that aripiprazole reduced recurrence compared with placebo (hazard ratio 0.53, 95% CI 0.32-0.87) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/36\">",
"     36",
"    </a>",
"    ]. A second trial also found that aripiprazole reduced recurrence (hazard ratio 0.54, 95% CI 0.33-0.89), whereas the third trial did not (hazard ratio 0.67, 95% CI 0.45-1.01). Aripiprazole appeared to primarily delay or prevent mania [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"     Aripiprazole",
"    </a>",
"    is initially started at a dose of 10 or 15 mg once per day, and can be increased to 15 or 30 mg once per day. Common side effects include tremor, akathisia, anxiety, nausea, dry mouth, and weight gain. Starting with a lower dose of 2 or 5 mg per day may help prevent side effects.",
"   </p>",
"   <p>",
"    Additional information about the pharmacology of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link&amp;anchor=H76524707#H76524707\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\", section on 'Aripiprazole'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Divalproex",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence for the efficacy of divalproex includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A one-year randomized trial assigned 279 patients to divalproex or placebo; recurrence occurred in significantly fewer patients who received divalproex compared with placebo (24 versus 38 percent), but time to recurrence did not differ significantly [",
"      <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/25,37\">",
"       25,37",
"      </a>",
"      ]. Divalproex appeared to delay or prevent depression more robustly than mania.",
"     </li>",
"     <li>",
"      An open-label, randomized study found that acute plus maintenance treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      was inferior to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/24\">",
"       24",
"      </a>",
"      ]. However, for patients who respond to acute treatment with divalproex, maintenance treatment with divalproex is superior compared with lithium or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Divalproex (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    ) is prescribed at a dose of 500 mg twice per day initially and titrated to achieve a target 12-hour serum trough level of 50 to 125",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    Long acting preparations are available that can be prescribed once per day. Common side effects from divalproex include somnolence, weight gain, gastrointestinal distress, elevated transaminases, tremor, decreased platelet counts, and alopecia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=see_link&amp;anchor=H19#H19\">",
"     \"Pharmacology of antiepileptic drugs\", section on 'Valproate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1453888\">",
"    <span class=\"h3\">",
"     Quetiapine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A two-year randomized maintenance trial found that time to recurrence of mania or depression were each significantly longer in patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    (N = 404, mean dose 546 mg per day) than placebo (N = 404) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/27\">",
"     27",
"    </a>",
"    ]. In addition, time to recurrence of depression was significantly longer with quetiapine than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    (N = 364, target trough serum concentration 0.6 to 1.2",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    [0.6 to 1.2",
"    <span class=\"nowrap\">",
"     mmol/L]).",
"    </span>",
"    Use of quetiapine plus lithium or divalproex as maintenance treatment is discussed elsewhere in this topic. (See",
"    <a class=\"local\" href=\"#H97783556\">",
"     'Lithium or divalproex plus a second generation antipsychotic'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H545524508\">",
"    <span class=\"h3\">",
"     Olanzapine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although multiple studies have found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    consistently delays or prevents recurrences [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/38,39\">",
"     38,39",
"    </a>",
"    ], we use olanzapine as a second-line maintenance treatment because it causes serious weight gain and may also cause diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/40-42\">",
"     40-42",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    Other side effects include increased cholesterol and triglycerides, dyspepsia, constipation, dry mouth, somnolence, fatigue, insomnia, extrapyramidal symptoms, and hyperprolactinemia (",
"    <a class=\"graphic graphic_table graphicRef82533 \" href=\"UTD.htm?32/57/33694\">",
"     table 1",
"    </a>",
"    ). The dose of olanzapine is usually 5 to 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    at bedtime. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link&amp;anchor=H76524686#H76524686\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\", section on 'Olanzapine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Five randomized maintenance trials with different designs have been performed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. As an example, a 48-week trial in 361 patients found relapse occurred in significantly fewer patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    compared with placebo (47 versus 80 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/38,43\">",
"     38,43",
"    </a>",
"    ]. In addition, the median time to relapse was longer in the group receiving olanzapine (174 versus 22 days). Olanzapine appeared to delay or prevent mania more effectively than major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other options",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/56/2951?source=see_link\">",
"     Asenapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    may be helpful for the many patients who are refractory to maintenance treatment with first- or second-line medications. However, the evidence supporting the use of these other options is inferior compared with first- and second-line drugs, as well as certain medication combinations. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'First line'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H9\">",
"     'Second line'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H16\">",
"     'Medication combinations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Asenapine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 49-week extension study was conducted with patients who completed a three-week randomized trial that compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/56/2951?source=see_link\">",
"     asenapine",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    for treatment of acute manic or mixed episodes; the efficacy of asenapine as maintenance treatment appeared comparable to olanzapine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/44\">",
"     44",
"    </a>",
"    ]. Asenapine is prescribed at a dose of 5 to 10 mg twice per day. Common side effects include weight gain, sedation, dizziness, insomnia, and extrapyramidal symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link&amp;anchor=H76524728#H76524728\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\", section on 'Asenapine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Carbamazepine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of four randomized controlled trials in which patients received maintenance treatment with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    found the two medications were similarly efficacious in preventing recurrence or hospitalization (none of the studies included a placebo arm) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/45\">",
"     45",
"    </a>",
"    ]. Carbamazepine is initially prescribed at a dose of 200 mg twice per day, and titrated up by increments of 200 mg per day; the maximum daily dose is 800 mg twice per day. A long-acting preparation can be given as a single daily dose. Many clinicians attempt to achieve a target 12-hour serum trough level of 4 to 8",
"    <span class=\"nowrap\">",
"     mcg/mL,",
"    </span>",
"    but there is no relationship between this blood level range and efficacy for maintenance treatment of bipolar disorder. Common side effects include dizziness, somnolence, ataxia, gastrointestinal distress, and elevated transaminases; a slow dose titration to below an individual&rsquo;s side effects threshold may help avoid these problems. Serious side effects include blood dyscrasias and life-threatening rashes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=see_link&amp;anchor=H3#H3\">",
"     \"Pharmacology of antiepileptic drugs\", section on 'Carbamazepine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Oxcarbazepine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review found insufficient evidence to recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    for maintenance treatment of bipolar disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/46\">",
"     46",
"    </a>",
"    ]. However, oxcarbazepine is an alternative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , based upon limited evidence of effectiveness in treating acute mood episodes and its structural similarity to carbamazepine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. In addition, oxcarbazepine is generally better tolerated and is easier to prescribe because it does not induce its own metabolism, as carbamazepine does.",
"   </p>",
"   <p>",
"    The initial dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    is 300 mg taken twice daily, which is titrated by 600",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    at weekly intervals to a target dose of 1200 to 2400",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    taken twice daily. Common side effects include dizziness, ocular disturbances, gastrointestinal distress, and somnolence. Clinicians should monitor serum sodium because oxcarbazepine can cause hyponatremia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=see_link&amp;anchor=H6#H6\">",
"     \"Pharmacology of antiepileptic drugs\", section on 'Oxcarbazepine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2534818\">",
"    <span class=\"h3\">",
"     Paliperidone",
"    </span>",
"    &nbsp;&mdash;&nbsp;A two year randomized maintenance trial compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/43/44728?source=see_link\">",
"     paliperidone",
"    </a>",
"    extended release (median dose 6 mg per day) with placebo in 290 patients with bipolar disorder who initially remitted from acute manic or mixed episodes with paliperidone [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/50\">",
"     50",
"    </a>",
"    ]. The median time to recurrence was longer in patients who received paliperidone than placebo (558 versus 283 days). The study also included 82 patients who remitted with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    and were maintained on it (median dose 10 mg per day). In this non-randomized arm, time to recurrence was longer with olanzapine than in either the randomized paliperidone or placebo arms.",
"   </p>",
"   <p>",
"    The usual starting dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/43/44728?source=see_link\">",
"     paliperidone",
"    </a>",
"    is 6 mg per day, and the dose can be adjusted by 3 mg increments every two to three days within a range of 3 to 12 mg per day. Common side effects include headache, somnolence, dizziness, nausea, and akathisia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Medication combinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapse frequently occurs despite maintenance monotherapy. The evidence supports using a medication combination (polypharmacy or polytherapy) for acute and maintenance treatment of these relapses.",
"   </p>",
"   <p>",
"    Most patients with multiple recurrences are subsequently treated for the acute mood episode with a medication combination [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]; the combination should be continued for maintenance treatment because the increased efficacy of medication combinations often outweighs the increased side effects and costs [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/54\">",
"     54",
"    </a>",
"    ]. In addition, for patients who have a partial but inadequate response to monotherapy that is tolerated, we suggest adding a second medication. Among the many possible medications combinations, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    or divalproex plus a second generation antipsychotic, which several trials have found is more efficacious than either lithium or divalproex monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/55-59\">",
"     55-59",
"    </a>",
"    ]. Lithium plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    are reasonable alternatives.",
"   </p>",
"   <p>",
"    The majority of randomized trials that have tested medication combinations have initially treated the acute mood episode with the combination. Following remission, patients were randomly assigned to maintenance treatment with the combination or monotherapy (by substituting placebo for one of the medications in the combination). &nbsp;",
"   </p>",
"   <p>",
"    Clinicians prescribing medication combinations for maintenance therapy should try to follow certain principles [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/60\">",
"     60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Attempt to prescribe only two medications, although three may be necessary",
"     </li>",
"     <li>",
"      The combination should not pose significantly greater safety or tolerability risks",
"     </li>",
"     <li>",
"      The combined drugs should not have the same or opposing mechanisms of action",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, clinicians need to be aware of possible pharmacokinetic interactions. As an example, divalproex (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    ) inhibits hepatic P450 enzymes and metabolism of concomitant medications. Conversely,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    induces hepatic enzymes and metabolism of concomitant medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97783556\">",
"    <span class=\"h3\">",
"     Lithium or divalproex plus a second generation antipsychotic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials have found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    or divalproex plus a second generation antipsychotic is superior to lithium or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    monotherapy for maintenance treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/55-59\">",
"     55-59",
"    </a>",
"    ]. In order of preference, we suggest adjunctive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    , long-acting injectable",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In two randomized trials (1334 total patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      or divalproex), relapse occurred in significantly fewer patients who received adjunctive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      compared with placebo (19 and 20 versus 49 and 52 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/55,56\">",
"       55,56",
"      </a>",
"      ]. Consistent with this finding, a pooled subgroup analysis of 445 patients with mixed episodes (concurrent mania and major depression) found that there were fewer recurrences with adjunctive quetiapine than placebo (21 versus 54 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/61\">",
"       61",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      In a randomized trial (124 patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , divalproex, and other medications), recurrence occurred in significantly fewer patients who received adjunctive long-acting injectable",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      compared with placebo (23 versus 46 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a randomized trial (240 patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      or divalproex), the median time to a mood episode was significantly longer in patients who received adjunctive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"       ziprasidone",
"      </a>",
"      compared with placebo (43 versus 27 days) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a randomized trial (68 asymptomatic patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      ), the median time to relapse of symptoms was significantly longer for adjunctive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      compared with placebo (163 versus 42 days) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/58\">",
"       58",
"      </a>",
"      ]. However, time to relapse of a mood syndrome (mania or depression) did not differ significantly between groups, nor did the number of patients with syndromic relapse.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional information about",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , divalproex,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    , long-acting injectable",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    is discussed separately. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Lithium'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H11\">",
"     'Divalproex'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link&amp;anchor=H76524693#H76524693\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\", section on 'Quetiapine'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H170721048\">",
"     'Risperidone intramuscular injection'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link&amp;anchor=H76524700#H76524700\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\", section on 'Ziprasidone'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H545524508\">",
"     'Olanzapine'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     Clozapine",
"    </a>",
"    added to any combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , anticonvulsants, antidepressants, or anxiolytics effectively delayed or prevented relapse of bipolar mood episodes in open-label prospective or retrospective studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. Clozapine can cause a potentially lethal agranulocytosis, and thus requires regular monitoring of white blood cell counts every one or two weeks. In addition, clozapine should not be combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    because they both adversely affect hematopoiesis. Additional information about the pharmacology of clozapine is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link&amp;anchor=H76524735#H76524735\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\", section on 'Clozapine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97783563\">",
"    <span class=\"h3\">",
"     Lithium plus an anticonvulsant",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    is often more effective than monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/24,65-68\">",
"     24,65-68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an open-label, randomized trial (330 patients), recurrence was reduced with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      compared with valproate monotherapy (hazard ratio 0.59, 95% CI 0.42-0.83) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a randomized trial (52 patients),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      led to significantly fewer mood episodes per year compared with lithium alone or carbamazepine alone (4.6 versus 6.3 and 6.7) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon our clinical experience,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    may also be effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H170721354\">",
"    <span class=\"h2\">",
"     Potentially problematic drugs",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11464920\">",
"    <span class=\"h3\">",
"     Antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of antidepressants for maintenance treatment of bipolar disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37417?source=see_link\">",
"     \"Bipolar disorder in adults: Treating major depression with antidepressants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H170721370\">",
"    <span class=\"h3\">",
"     Benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines during maintenance treatment may be associated with an increased risk of recurrence. An observational study from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) examined 1365 patients who recovered from a mood episode [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/69\">",
"     69",
"    </a>",
"    ]. After adjusting for potential confounds, use of a benzodiazepine on a standing or as-needed basis following recovery was associated with an increased risk of recurrence (hazard ratio 1.21, 95% CI 1.01-1.45). Comparable effects were observed in additional analyses, including one that stratified the sample by propensity score (a summary measure of the likelihood of receiving a benzodiazepine). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259506092\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of maintenance treatment will vary for each patient. Most patients require maintenance treatment for many years, and some patients require it their entire lives. Factors to consider include how many years the patient has had bipolar disorder and the number of mood episodes and hospitalizations that have occurred. Maintenance treatment should last longer for patients with a more severe course of illness. For female patients, the decision to conceive children may interrupt treatment. Intolerable side effects may truncate maintenance treatment altogether, but clinicians should first try to find better tolerated alternatives.",
"   </p>",
"   <p>",
"    Some patients are discouraged by the prospect of taking their medication \"forever.\" In such cases, it is important to emphasize the long-term nature of the relationship between the clinician and patient, and that the need for maintenance treatment will periodically be reevaluated in light of the patient's progress in maintaining symptomatic and functional stability. It may also help to point out that other chronic illnesses such as hypertension, diabetes mellitus, and asthma often require life-time medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1205113\">",
"    <span class=\"h3\">",
"     Adherence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients have difficulty adhering to (complying with) maintenance treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/70-73\">",
"     70-73",
"    </a>",
"    ]. Several strategies that can improve adherence may be feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/71,74,75\">",
"     71,74,75",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identify poor adherence &ndash; markers include missed appointments, lack of response to treatment, missed refills",
"     </li>",
"     <li>",
"      Obtain help from family members",
"     </li>",
"     <li>",
"      Provide psychoeducation for patients and family members",
"     </li>",
"     <li>",
"      Ask about the patient&rsquo;s ability to follow the regimen and address barriers to adherence",
"     </li>",
"     <li>",
"      Emphasize benefits of the regimen that are important to the patient",
"     </li>",
"     <li>",
"      Customize the regimen according to the patient&rsquo;s wishes",
"     </li>",
"     <li>",
"      Simplify the regimen",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Minimize the number of medications",
"     </li>",
"     <li>",
"      Prescribe medications that are dosed once or twice per day",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Provide simple, clear instructions for taking the medication",
"     </li>",
"     <li>",
"      Use pill boxes to organize daily doses",
"     </li>",
"     <li>",
"      Suggest the patient use cues as a reminder to take medications",
"     </li>",
"     <li>",
"      Increase the hours when the clinic is open, including evening hours",
"     </li>",
"     <li>",
"      Reinforce desirable behavior and results",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Psychoeducation is discussed separately. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Psychoeducation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15312584\">",
"    <span class=\"h2\">",
"     Discontinuation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients require maintenance treatment for many years, and some patients require it for their entire lives. However, patients may want to stop maintenance medications because of side effects, inadequate response, medical illness, pregnancy, or a wish to be medication-free after a prolonged period of euthymia. Discontinuing stable treatment usually leads to a new mood episode:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of 14",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      maintenance treatment studies that involved discontinuation of lithium in 257 patients who had previously been stable for a mean of 30 months, more than 50 percent of the patients suffered a recurrence within 10 weeks of discontinuing lithium, and about 90 percent relapsed within the first year off of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a subsequent study, among 32 patients successfully treated with maintenance",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      for a minimum of five years, 32 percent suffered a recurrence within one month of discontinuing lithium, and 62 percent within one year [",
"      <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other risks of stopping maintenance treatment include hospitalization, persistent subsyndromal symptoms, family and economic losses, and suicide. Psychoeducation may help discourage patients from discontinuing effective maintenance treatment. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Psychoeducation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If patients insist on stopping treatment, we suggest slowly tapering one medication at a time, over a period of several weeks to months. Clinicians should also monitor patients frequently for prodromal symptoms of early recurrence. Prospective, open-label studies show that tapering maintenance medication more slowly is associated with lower rates of recurrence, but that most patients suffer a recurrence despite the slower taper:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 78 patients who were effectively maintained on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      for a mean of four years and then discontinued it, recurrence within two years was significantly greater in patients who stopped lithium in less than two weeks compared with discontinuation over two to four weeks (95 versus 69 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In 64 patients who were stable on maintenance",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      for a mean of four years and then discontinued it, recurrence within five years was significantly greater in patients who stopped lithium in less than two weeks compared with discontinuation over two to four weeks (94 versus 53 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     ADJUNCTIVE PSYCHOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although pharmacotherapy is the cornerstone of maintenance treatment, combining pharmacotherapy with psychotherapy is more efficacious for both short- and longer-term outcomes, compared with pharmacotherapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. Adjunctive psychotherapy can help patients accept their chronic illness and thus promote medication adherence, early detection of prodromal symptoms, and behavioral changes and improved functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/1,82\">",
"     1,82",
"    </a>",
"    ]. In addition, psychotherapy may minimize recurrence by ameliorating stress and interpersonal conflicts and helping patients cope with the psychosocial consequences of prior mood episodes, ongoing subsyndromal symptoms, and fear of future recurrent episodes. Patients should ideally be euthymic prior to initiating psychotherapy.",
"   </p>",
"   <p>",
"    Different options include, in order of preference:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Psychoeducation",
"     </li>",
"     <li>",
"      Cognitive-behavioral therapy",
"     </li>",
"     <li>",
"      Marital and family therapy",
"     </li>",
"     <li>",
"      Interpersonal and social rhythm therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If adjunctive psychotherapy is used during treatment of an acute mood episode, maintenance psychotherapy usually consists of the same psychotherapy. This practice is supported by a randomized trial of 82 patients with acute mood episodes who were stabilized for four weeks with pharmacotherapy plus one of two randomly assigned adjunctive psychotherapies (either interpersonal and social rhythm therapy or the control therapy, called intensive clinical management) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/83\">",
"     83",
"    </a>",
"    ]. Following stabilization, patients were randomly assigned again to maintenance treatment with the same psychotherapy or to switch to the other psychotherapy. Relapse occurred in significantly fewer patients who maintained the same therapy compared with those who switched (18 versus 40 percent).",
"   </p>",
"   <p>",
"    Maintenance psychotherapy can be provided in a group or individual format. In addition, different types of psychotherapies can be combined with each other [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/82\">",
"     82",
"    </a>",
"    ]. All of these therapies are structured and some are time-limited.",
"   </p>",
"   <p>",
"    A meta-analysis of nine randomized trials (721 patients) found that adjunctive psychologic therapies specifically adapted for bipolar disorder (psychoeducation, cognitive-behavioral therapy, or family-focused therapy) reduced the probability of recurrence by 26 percent (relative risk 0.74, 95% CI 0.64-0.85) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized trial (293 outpatients) not included in the meta-analysis compared three forms of psychotherapy over nine months (family-focused, interpersonal and social rhythm, or cognitive-behavioral therapy) with a \"collaborative care\" approach (three sessions over six weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/84\">",
"     84",
"    </a>",
"    ]. Patients receiving psychotherapy were significantly more likely to be well during any study month, especially in later months, suggesting that psychotherapy was useful in preventing relapse. Compared to collaborative care, psychotherapy also improved some aspects of social functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/85\">",
"     85",
"    </a>",
"    ]. The three types of psychotherapy did not differ significantly for any of the outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Psychoeducation",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest psychoeducation as part of maintenance treatment for all patients with bipolar disorder. Psychoeducation is a structured, time limited program that teaches patients and family members about bipolar disorder, including its etiology, clinical features, diagnosis, treatment, and course of illness. In addition, adherence to treatment and coping skills are reinforced. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Information for patients'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7545?source=see_link&amp;anchor=H13494676#H13494676\">",
"     \"Geriatric bipolar disorder: Epidemiology, clinical features, assessment, and diagnosis\", section on 'Information for patients'",
"    </a>",
"    .) Nearly all other types of psychotherapy include an element of psychoeducation because of its demonstrated success and the ease of administration.",
"   </p>",
"   <p>",
"    Psychoeducation prevents recurrences and hospitalizations, and improves psychosocial functioning:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of six randomized trials (690 patients with bipolar disorder) compared treatment as usual (medication and outpatient appointments with a psychiatrist) with psychoeducation (recognizing and managing prodromal symptoms) plus treatment as usual [",
"      <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/86\">",
"       86",
"      </a>",
"      ]. Psychoeducation reduced recurrence (hazard ratio 0.57, 95% CI 0.39-0.82). In addition, psychoeducation significantly reduced hospitalizations by 33 percent (12 versus 18 percent of patients) and led to significantly better social functioning 18 months after baseline.",
"     </li>",
"     <li>",
"      A randomized trial (84 patients with bipolar disorder) not included in the meta-analysis evaluated adjunctive psychoeducation that focused upon monitoring prodromal symptoms, skills to manage everyday life situations, and setting goals [",
"      <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/87\">",
"       87",
"      </a>",
"      ]. Recurrence was reduced in patients who received psychoeducation plus pharmacotherapy compared with pharmacotherapy alone (hazard ratio 0.43, 95% CI 0.20-0.95).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Cognitive-behavioral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive-behavioral therapy (CBT) systematically addresses dysfunctional thoughts, emotions, and behaviors by helping patients think more positively about themselves and to change their behavior by setting realistic and observable goals. CBT may also include educating patients about bipolar disorder and teaching coping skills for psychosocial stressors. A meta-analysis of three randomized trials (150 patients) found relapse occurred in significantly fewer patients who received adjunctive CBT compared with the control group (49 versus 79 percent of patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13270926\">",
"    <span class=\"h2\">",
"     Other options",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternatives include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Family therapy &ndash;",
"      </strong>",
"      Family therapy encompasses different types of interventions that vary in their theoretical orientation and focus. The therapy may address relationships between family members, behavioral change, communication, problem-solving skills, psychoeducation, or the need to view the family as a single system. Evidence that family therapy prevents recurrences is inconsistent. Two systematic reviews found adjunctive family therapy provided no additional benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/88,89\">",
"       88,89",
"      </a>",
"      ]. However, another review concluded family therapy effectively prevented relapse and improved functional outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Interpersonal and social rhythm therapy &ndash;",
"      </strong>",
"      This therapy helps patients resolve interpersonal problems related to grief, role transitions, role disputes, and interpersonal deficits, and helps patients stabilize their daily routines and",
"      <span class=\"nowrap\">",
"       sleep/wake",
"      </span>",
"      cycles. A two-year randomized trial with 175 patients found that time to recurrence did not differ significantly between maintenance treatment with adjunctive interpersonal and social rhythm therapy compared with the adjunctive control treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/90\">",
"       90",
"      </a>",
"      ]. However, acute phase treatment with adjunctive interpersonal and social rhythm therapy may increase time to recurrence of a subsequent mood episode.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11465621\">",
"    <span class=\"h1\">",
"     ELECTROCONVULSIVE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance electroconvulsive therapy (ECT) has been used for patients who responded to ECT for treatment of acute mood episodes and failed many other maintenance medication regimens and psychotherapies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/1\">",
"     1",
"    </a>",
"    ]. Most of the evidence supporting the effectiveness and tolerability of maintenance ECT comes from case reports and small case series; the frequency of maintenance ECT ranged from once a week to once a month [",
"    <a class=\"abstract\" href=\"UTD.htm?27/9/27802/abstract/91-97\">",
"     91-97",
"    </a>",
"    ]. Maintenance medications, including anticonvulsants, are often prescribed in conjunction with maintenance ECT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28812346\">",
"    <span class=\"h1\">",
"     GERIATRIC PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance treatment for geriatric bipolar disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22601?source=see_link\">",
"     \"Geriatric bipolar disorder: Maintenance treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H263769161\">",
"    <span class=\"h1\">",
"     FEMALE PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For female patients who are at high risk of unintended pregnancies (eg, become hypersexual when manic or have a history of irregular use of contraceptives), we try to avoid using teratogenic drugs, especially",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    , but also",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    . The malformations caused by these drugs are discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11226?source=see_link\">",
"     \"Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4468938\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preconception and prenatal maintenance pharmacotherapy for bipolar patients, and contraception and preconception counseling for bipolar disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/51/2874?source=see_link\">",
"     \"Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25638?source=see_link\">",
"     \"Bipolar disorder in women: Indications for preconception and prenatal maintenance pharmacotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/24/40329?source=see_link\">",
"     \"Bipolar disorder in women: Contraception and preconception assessment and counseling\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (See",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/5/4178?source=see_link\">",
"       \"Patient information: Bipolar disorder (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (The Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/55/39796?source=see_link\">",
"       \"Patient information: Bipolar disorder (manic depression) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These educational materials can be used as part of psychoeducational psychotherapy. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Psychoeducation'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p>",
"    The National Institute of Mental Health also has educational material explaining the symptoms, course of illness, and treatment of bipolar disorder in a booklet entitled \"Bipolar Disorder,\" which is available online at the website",
"    <a class=\"external\" href=\"file://www.nimh.nih.gov/health/publications/bipolar-disorder/complete-index.shtml\">",
"     file://www.nimh.nih.gov/health/publications/bipolar-disorder/complete-index.shtml",
"    </a>",
"    or through a toll-free number, 866-615-6464. The web site also provides references, summaries of study results in language intended for the lay public, and information about clinical trials currently recruiting patients.",
"   </p>",
"   <p>",
"    More comprehensive information is provided in many books written for patients and family members, including The Bipolar Disorder Survival Guide: What You and Your Family Need to Know, written by David J. Miklowitz, PhD (published by The Guilford Press, 2002); An Unquiet Mind: A Memoir of Moods and Madness, written by Kay Jamison, PhD (published by Random House, 1995); and Treatment of Bipolar Illness: A Casebook for Clinicians and Patients, by RM Post, MD, and GS Leverich, LCSW (published by Norton Press, 2008).",
"   </p>",
"   <p>",
"    The Depression and Bipolar Support Alliance (",
"    <a class=\"external\" href=\"file://www.dbsalliance.org/\">",
"     file://www.dbsalliance.org",
"    </a>",
"    or 800-826-3632) is a national organization that educates members about bipolar disorder and how to cope with it. Other functions include increasing public awareness of the illness and advocating for more research and services. The organization is administered and maintained by patients and family members, and has local chapters.",
"   </p>",
"   <p>",
"    The National Alliance on Mental Illness (",
"    <a class=\"external\" href=\"file://www.nami.org/\">",
"     file://www.nami.org",
"    </a>",
"    or 800-950-6264) is a similarly structured organization devoted to education, support, and advocacy for patients with any mental illness. Bipolar disorder is one of their priorities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bipolar disorder is a highly recurrent illness. For patients with bipolar I disorder, we recommend maintenance pharmacotherapy rather than no treatment (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We also suggest maintenance treatment for patients with bipolar II disorder rather than no treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Patients with bipolar disorder not otherwise specified are likely to benefit from maintenance treatment as well. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goals for maintenance therapy are to reduce subsyndromal symptoms, delay or prevent recurrence of new mood episodes, reduce the risk of suicide, and promote psychosocial functioning. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For initial maintenance therapy in most patients, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      monotherapy over other medication regimens (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Lithium is dosed to achieve a 12-hour serum trough level of 0.8 to 1.2",
"      <span class=\"nowrap\">",
"       mEq/L,",
"      </span>",
"      which can be reduced to 0.6",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      or lower for patients unable to tolerate higher levels. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'First line'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are unresponsive to or intolerant of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      or long-acting injectable",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      )&nbsp;(see",
"      <a class=\"local\" href=\"#H4\">",
"       'First line'",
"      </a>",
"      above). For patients who do not respond to or cannot tolerate these drugs,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"       aripiprazole",
"      </a>",
"      , divalproex,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      are reasonable alternatives. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Second line'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have a history of multiple recurrences and have a partial but inadequate response to a maintenance drug that is tolerated, we suggest adding a second medication (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Common combinations include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      , plus a second generation antipsychotic, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      , long-acting injectable",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"       ziprasidone",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      . Other combinations that are useful include lithium plus valproate or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Medication combinations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Psychotherapy as adjunctive treatment with pharmacotherapy can prevent recurrences and hospitalizations. For patients with bipolar disorder, we suggest adjunctive psychoeducation for euthymic patients rather than no psychotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Cognitive behavior therapy is a reasonable alternative to psychoeducation. Either psychoeducation or cognitive behavioral therapy, or both, can be added to pharmacotherapy. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Adjunctive psychotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients require maintenance treatment for many years, and some patients require it their entire lives. (See",
"      <a class=\"local\" href=\"#H259506092\">",
"       'Duration'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/1\">",
"      American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/2\">",
"      Goodwin GM, Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009; 23:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/3\">",
"      Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009; 11:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/4\">",
"      Perlis RH, Ostacher MJ, Patel JK, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2006; 163:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/5\">",
"      Keller MB, Lavori PW, Coryell W, et al. Bipolar I: a five-year prospective follow-up. J Nerv Ment Dis 1993; 181:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/6\">",
"      Leverich GS, Altshuler LL, Frye MA, et al. Factors associated with suicide attempts in 648 patients with bipolar disorder in the Stanley Foundation Bipolar Network. J Clin Psychiatry 2003; 64:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/7\">",
"      Oquendo MA, Mann JJ. Identifying and managing suicide risk in bipolar patients. J Clin Psychiatry 2001; 62 Suppl 25:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/8\">",
"      Rucci P, Frank E, Kostelnik B, et al. Suicide attempts in patients with bipolar I disorder during acute and maintenance phases of intensive treatment with pharmacotherapy and adjunctive psychotherapy. Am J Psychiatry 2002; 159:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/9\">",
"      Slama F, Bellivier F, Henry C, et al. Bipolar patients with suicidal behavior: toward the identification of a clinical subgroup. J Clin Psychiatry 2004; 65:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/10\">",
"      Fagiolini A, Kupfer DJ, Rucci P, et al. Suicide attempts and ideation in patients with bipolar I disorder. J Clin Psychiatry 2004; 65:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/11\">",
"      Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord 2002; 68:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/12\">",
"      Nolen WA, Luckenbaugh DA, Altshuler LL, et al. Correlates of 1-year prospective outcome in bipolar disorder: results from the Stanley Foundation Bipolar Network. Am J Psychiatry 2004; 161:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/13\">",
"      Yurgelun-Todd D. Neurocognitive deficits in bipolar disorder. Clinical Approaches in Bipolar Disorder 2006; 5:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/14\">",
"      Post RM. Mechanisms of illness progression in the recurrent affective disorders. Neurotox Res 2010; 18:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/15\">",
"      Post RM, Altshuler LL, Frye MA, et al. Complexity of pharmacologic treatment required for sustained improvement in outpatients with bipolar disorder. J Clin Psychiatry 2010; 71:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/16\">",
"      Kashner TM, Rush AJ, Crismon ML, et al. An empirical analysis of cost outcomes of the Texas Medication Algorithm Project. Psychiatr Serv 2006; 57:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/17\">",
"      Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003; 60:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/18\">",
"      Grunze H, Kasper S, Goodwin G, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment. World J Biol Psychiatry 2004; 5:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/19\">",
"      Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 2011; 68:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/20\">",
"      Smith DJ, Griffiths E, Kelly M, et al. Unrecognised bipolar disorder in primary care patients with depression. Br J Psychiatry 2011; 199:49.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/22\">",
"      Malhi GS, Adams D, Cahill CM, et al. The management of individuals with bipolar disorder: a review of the evidence and its integration into clinical practice. Drugs 2009; 69:2063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/23\">",
"      McElroy SL, Bowden CL, Collins MA, et al. Relationship of open acute mania treatment to blinded maintenance outcome in bipolar I disorder. J Affect Disord 2008; 107:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/24\">",
"      BALANCE investigators and collaborators, Geddes JR, Goodwin GM, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010; 375:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/25\">",
"      Smith LA, Cornelius V, Warnock A, et al. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord 2007; 9:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/26\">",
"      Geddes JR, Burgess S, Hawton K, et al. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004; 161:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/27\">",
"      Weisler RH, Nolen WA, Neijber A, et al. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry 2011; 72:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/28\">",
"      Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 2005; 162:1805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/29\">",
"      Baldessarini RJ, Tondo L, Hennen J. Treating the suicidal patient with bipolar disorder. Reducing suicide risk with lithium. Ann N Y Acad Sci 2001; 932:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/30\">",
"      Kessing LV, S&oslash;nderg&aring;rd L, Kvist K, Andersen PK. Suicide risk in patients treated with lithium. Arch Gen Psychiatry 2005; 62:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/31\">",
"      Goodwin FK, Fireman B, Simon GE, et al. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 2003; 290:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/32\">",
"      Bowden CL, Asnis GM, Ginsberg LD, et al. Safety and tolerability of lamotrigine for bipolar disorder. Drug Saf 2004; 27:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/33\">",
"      Deeks ED. Risperidone long-acting injection: in bipolar I disorder. Drugs 2010; 70:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/34\">",
"      Quiroz JA, Yatham LN, Palumbo JM, et al. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry 2010; 68:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/35\">",
"      Yatham LN. A clinical review of aripiprazole in bipolar depression and maintenance therapy of bipolar disorder. J Affect Disord 2011; 128 Suppl 1:S21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/36\">",
"      Keck PE Jr, Calabrese JR, McIntyre RS, et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007; 68:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/37\">",
"      Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000; 57:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/38\">",
"      Cipriani A, Rendell JM, Geddes J. Olanzapine in long-term treatment for bipolar disorder. Cochrane Database Syst Rev 2009; :CD004367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/39\">",
"      Cipriani A, Rendell J, Geddes JR. Olanzapine in the long-term treatment of bipolar disorder: a systematic review and meta-analysis. J Psychopharmacol 2010; 24:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/40\">",
"      Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 2004; 161:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/41\">",
"      Fernandez-Egea E, Miller B, Garcia-Rizo C, et al. Metabolic effects of olanzapine in patients with newly diagnosed psychosis. J Clin Psychopharmacol 2011; 31:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/42\">",
"      Raedler TJ. Cardiovascular aspects of antipsychotics. Curr Opin Psychiatry 2010; 23:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/43\">",
"      Tohen M, Calabrese JR, Sachs GS, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006; 163:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/44\">",
"      McIntyre RS, Cohen M, Zhao J, et al. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. J Affect Disord 2010; 126:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/45\">",
"      Ceron-Litvoc D, Soares BG, Geddes J, et al. Comparison of carbamazepine and lithium in treatment of bipolar disorder: a systematic review of randomized controlled trials. Hum Psychopharmacol 2009; 24:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/46\">",
"      Vasudev A, Macritchie K, Watson S, et al. Oxcarbazepine in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev 2008; :CD005171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/47\">",
"      Pratoomsri W, Yatham LN, Bond DJ, et al. Oxcarbazepine in the treatment of bipolar disorder: a review. Can J Psychiatry 2006; 51:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/48\">",
"      Popova E, Leighton C, Bernabarre A, et al. Oxcarbazepine in the treatment of bipolar and schizoaffective disorders. Expert Rev Neurother 2007; 7:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/49\">",
"      Mazza M, Di Nicola M, Martinotti G, et al. Oxcarbazepine in bipolar disorder: a critical review of the literature. Expert Opin Pharmacother 2007; 8:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/50\">",
"      Berwaerts J, Melkote R, Nuamah I, Lim P. A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode. J Affect Disord 2012; 138:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/51\">",
"      Goldberg JF, Brooks JO 3rd, Kurita K, et al. Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. J Clin Psychiatry 2009; 70:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/52\">",
"      Blanco C, Laje G, Olfson M, et al. Trends in the treatment of bipolar disorder by outpatient psychiatrists. Am J Psychiatry 2002; 159:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/53\">",
"      Wolfsperger M, Greil W, R&ouml;ssler W, Grohmann R. Pharmacological treatment of acute mania in psychiatric in-patients between 1994 and 2004. J Affect Disord 2007; 99:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/54\">",
"      Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 2009; 10:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/55\">",
"      Suppes T, Vieta E, Liu S, et al. Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 2009; 166:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/56\">",
"      Vieta E, Suppes T, Eggens I, et al. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 2008; 109:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/57\">",
"      Macfadden W, Alphs L, Haskins JT, et al. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord 2009; 11:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/58\">",
"      Tohen M, Chengappa KN, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004; 184:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/59\">",
"      Bowden CL, Vieta E, Ice KS, et al. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 2010; 71:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/60\">",
"      Preskorn SH, Lacey RL. Polypharmacy: when is it rational? J Psychiatr Pract 2007; 13:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/61\">",
"      Vieta E, Suppes T, Ekholm B, et al. Long-term efficacy of quetiapine in combination with lithium or divalproex on mixed symptoms in bipolar I disorder. J Affect Disord 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/62\">",
"      Suppes T, Webb A, Paul B, et al. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999; 156:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/63\">",
"      Ciapparelli A, Dell'Osso L, Bandettini di Poggio A, et al. Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. J Clin Psychiatry 2003; 64:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/64\">",
"      Chang JS, Ha KS, Young Lee K, et al. The effects of long-term clozapine add-on therapy on the rehospitalization rate and the mood polarity patterns in bipolar disorders. J Clin Psychiatry 2006; 67:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/65\">",
"      Denicoff KD, Smith-Jackson EE, Bryan AL, et al. Valproate prophylaxis in a prospective clinical trial of refractory bipolar disorder. Am J Psychiatry 1997; 154:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/66\">",
"      Bocchetta A, Chillotti C, Severino G, et al. Carbamazepine augmentation in lithium-refractory bipolar patients: a prospective study on long-term prophlyactic effectiveness. J Clin Psychopharmacol 1997; 17:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/67\">",
"      Baethge C, Baldessarini RJ, Mathiske-Schmidt K, et al. Long-term combination therapy versus monotherapy with lithium and carbamazepine in 46 bipolar I patients. J Clin Psychiatry 2005; 66:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/68\">",
"      Denicoff KD, Smith-Jackson EE, Disney ER, et al. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997; 58:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/69\">",
"      Perlis RH, Ostacher MJ, Miklowitz DJ, et al. Benzodiazepine use and risk of recurrence in bipolar disorder: a STEP-BD report. J Clin Psychiatry 2010; 71:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/70\">",
"      Perlis RH, Ostacher MJ, Miklowitz DJ, et al. Clinical features associated with poor pharmacologic adherence in bipolar disorder: results from the STEP-BD study. J Clin Psychiatry 2010; 71:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/71\">",
"      Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009; 70 Suppl 4:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/72\">",
"      Kessing LV, S&oslash;nderg&aring;rd L, Kvist K, Andersen PK. Adherence to lithium in naturalistic settings: results from a nationwide pharmacoepidemiological study. Bipolar Disord 2007; 9:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/73\">",
"      Sajatovic M, Valenstein M, Blow FC, et al. Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord 2006; 8:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/74\">",
"      Colom F, Vieta E, Tacchi MJ, et al. Identifying and improving non-adherence in bipolar disorders. Bipolar Disord 2005; 7 Suppl 5:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/75\">",
"      Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/76\">",
"      Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991; 48:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/77\">",
"      Yazici O, Kora K, Polat A, Saylan M. Controlled lithium discontinuation in bipolar patients with good response to long-term lithium prophylaxis. J Affect Disord 2004; 80:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/78\">",
"      Baldessarini RJ, Tondo L, Floris G, Rudas N. Reduced morbidity after gradual discontinuation of lithium treatment for bipolar I and II disorders: a replication study. Am J Psychiatry 1997; 154:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/79\">",
"      Faedda GL, Tondo L, Baldessarini RJ, et al. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders. Arch Gen Psychiatry 1993; 50:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/80\">",
"      Miklowitz DJ. Adjunctive psychotherapy for bipolar disorder: state of the evidence. Am J Psychiatry 2008; 165:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/81\">",
"      Lam DH, Burbeck R, Wright K, Pilling S. Psychological therapies in bipolar disorder: the effect of illness history on relapse prevention - a systematic review. Bipolar Disord 2009; 11:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/82\">",
"      Rothbaum BO, Astin MC. Integration of pharmacotherapy and psychotherapy for bipolar disorder. J Clin Psychiatry 2000; 61 Suppl 9:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/83\">",
"      Frank E, Swartz HA, Mallinger AG, et al. Adjunctive psychotherapy for bipolar disorder: effects of changing treatment modality. J Abnorm Psychol 1999; 108:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/84\">",
"      Miklowitz DJ, Otto MW, Frank E, et al. Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Arch Gen Psychiatry 2007; 64:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/85\">",
"      Miklowitz DJ, Otto MW, Frank E, et al. Intensive psychosocial intervention enhances functioning in patients with bipolar depression: results from a 9-month randomized controlled trial. Am J Psychiatry 2007; 164:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/86\">",
"      Morriss RK, Faizal MA, Jones AP, et al. Interventions for helping people recognise early signs of recurrence in bipolar disorder. Cochrane Database Syst Rev 2007; :CD004854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/87\">",
"      Castle D, White C, Chamberlain J, et al. Group-based psychosocial intervention for bipolar disorder: randomised controlled trial. Br J Psychiatry 2010; 196:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/88\">",
"      Beynon S, Soares-Weiser K, Woolacott N, et al. Psychosocial interventions for the prevention of relapse in bipolar disorder: systematic review of controlled trials. Br J Psychiatry 2008; 192:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/89\">",
"      Justo LP, Soares BG, Calil HM. Family interventions for bipolar disorder. Cochrane Database Syst Rev 2007; :CD005167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/90\">",
"      Frank E, Kupfer DJ, Thase ME, et al. Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry 2005; 62:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/91\">",
"      Zisselman MH, Rosenquist PB, Curlik SM. Long-term weekly continuation electroconvulsive therapy: a case series. J ECT 2007; 23:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/92\">",
"      Yero SA, McKinney T, Petrides G, et al. Successful use of electroconvulsive therapy in 2 cases of persistent sexual arousal syndrome and bipolar disorder. J ECT 2006; 22:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/93\">",
"      Sienaert P, Peuskens J. Electroconvulsive therapy: an effective therapy of medication-resistant bipolar disorder. Bipolar Disord 2006; 8:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/94\">",
"      Nascimento AL, Appolinario JC, Segenreich D, et al. Maintenance electroconvulsive therapy for recurrent refractory mania. Bipolar Disord 2006; 8:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/95\">",
"      Tsao CI, Jain S, Gibson RH, et al. Maintenance ECT for recurrent medication-refractory mania. J ECT 2004; 20:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/96\">",
"      Vaidya NA, Mahableshwarkar AR, Shahid R. Continuation and maintenance ECT in treatment-resistant bipolar disorder. J ECT 2003; 19:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/9/27802/abstract/97\">",
"      Russell JC, Rasmussen KG, O'Connor MK, et al. Long-term maintenance ECT: a retrospective review of efficacy and cognitive outcome. J ECT 2003; 19:4.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 680 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-18C9BB78CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_9_27802=[""].join("\n");
var outline_f27_9_27802=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H259506221\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHARMACOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      First line",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Lithium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H259506193\">",
"      Reduced risk of suicide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Lamotrigine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H170721048\">",
"      - Risperidone intramuscular injection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Second line",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Aripiprazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Divalproex",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1453888\">",
"      - Quetiapine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H545524508\">",
"      - Olanzapine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other options",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Asenapine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Carbamazepine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Oxcarbazepine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2534818\">",
"      - Paliperidone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Medication combinations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H97783556\">",
"      - Lithium or divalproex plus a second generation antipsychotic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H97783563\">",
"      - Lithium plus an anticonvulsant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H170721354\">",
"      Potentially problematic drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11464920\">",
"      - Antidepressants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H170721370\">",
"      - Benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H259506092\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1205113\">",
"      - Adherence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15312584\">",
"      Discontinuation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      ADJUNCTIVE PSYCHOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Psychoeducation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Cognitive-behavioral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13270926\">",
"      Other options",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11465621\">",
"      ELECTROCONVULSIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28812346\">",
"      GERIATRIC PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H263769161\">",
"      FEMALE PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4468938\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/680\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/680|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/57/33694\" title=\"table 1\">",
"      Adverse effects for antipsychotic meds",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/3/43065?source=related_link\">",
"      Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=related_link\">",
"      Bipolar disorder in adults: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/3/44088?source=related_link\">",
"      Bipolar disorder in adults: Pharmacotherapy for acute depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38026?source=related_link\">",
"      Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11226?source=related_link\">",
"      Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37417?source=related_link\">",
"      Bipolar disorder in adults: Treating major depression with antidepressants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/24/40329?source=related_link\">",
"      Bipolar disorder in women: Contraception and preconception assessment and counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25638?source=related_link\">",
"      Bipolar disorder in women: Indications for preconception and prenatal maintenance pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/51/2874?source=related_link\">",
"      Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7545?source=related_link\">",
"      Geriatric bipolar disorder: Epidemiology, clinical features, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22601?source=related_link\">",
"      Geriatric bipolar disorder: Maintenance treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/5/4178?source=related_link\">",
"      Patient information: Bipolar disorder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/55/39796?source=related_link\">",
"      Patient information: Bipolar disorder (manic depression) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=related_link\">",
"      Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_9_27803="Estimating calories";
var content_f27_9_27803=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F66100&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F66100&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Estimating calories for weight maintenance",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Men:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        662 - (9.53 x age [year]) + PA* x (15.91 x weight [kg] + 539.6 x height [m])",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        * The PA coefficient is:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        sedentary = 1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        low active = 1.11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        active = 1.25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        very active = 1.48",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Women:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        354 - (6.91 x age [year]) + PA&bull; x (9.36 x weight [kg] + 726 x height [m])",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull; The PA coefficient is:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        sedentary = 1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        low active = 1.12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        active = 1.27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        very active = 1.45",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Institutes of Medicine, Food and Nutrition Board. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids. Washington, DC: National Academy Press 2002.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_9_27803=[""].join("\n");
var outline_f27_9_27803=null;
var title_f27_9_27804="Agents that reduce intraocular pressure";
var content_f27_9_27804=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F76771&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F76771&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Agents that reduce intraocular pressure",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"25%\">",
"     </colgroup>",
"     <colgroup width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Class",
"       </td>",
"       <td class=\"subtitle1\">",
"        Examples",
"       </td>",
"       <td class=\"subtitle1\">",
"        Side effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Agents that suppress aqueous inflow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &beta; adrenergic blockers",
"       </td>",
"       <td>",
"        Betaxolol, carteolol, levobunolol, metipranolol, timolol",
"       </td>",
"       <td>",
"        Ocular irritation and dry eyes. Contraindicated in patients with bradycardia, heart block, heart failure, asthma, or obstructive airway disease.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &alpha;",
"        <sub>",
"         2",
"        </sub>",
"        adrenergic agonists",
"       </td>",
"       <td>",
"        Apraclonidine, brimonidine",
"       </td>",
"       <td>",
"        Red eye and ocular irritation. CNS effects and respiratory arrest in young children (brimonidine). Caution in patients with cerebral or coronary insufficiency, Raynauds, postural hypotension, hepatic or renal impairment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Carbonic anhydrase inhibitors",
"       </td>",
"       <td>",
"        Dorzolamide and brinzolamide (topical), acetazolamide and methazolamide (oral)",
"       </td>",
"       <td>",
"        Oral form can cause transient myopia, nausea, diarrhea, loss of appetite and taste, parasthesiae, lassitude, renal stones, and hematological problems. Topical forms much less likely to cause systemic side-effects but can cause local irritation and redness.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Agents that increase aqueous outflow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prostaglandin analogues, (prostamide)",
"       </td>",
"       <td>",
"        Brimatoprost, latanoprost, tafluprost, travoprost, unoprostone*",
"       </td>",
"       <td>",
"        Brown discoloration of iris, lengthening and darkening of eyelashes, ocular irritation and redness, macular edema or iritis in susceptible individuals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &alpha; adrenergic agonists",
"       </td>",
"       <td>",
"        Apraclonidine, brimonidine",
"       </td>",
"       <td>",
"        Red eye and ocular irritation. CNS effects and respiratory arrest in young children (brimonidine). Caution in patients with cerebral or coronary insufficiency, Raynauds, postural hypotension, hepatic or renal impairment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cholinergic agonists",
"       </td>",
"       <td>",
"        Pilocarpine, carbachol",
"       </td>",
"       <td>",
"        Ciliary spasm leading to headaches especially in younger patients, myopia, dim vision (small pupil). Cataracts and iris-lens adhesions in long term.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Not available in US or Canada.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004; 363:1711. Copyright &copy; 2004 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_9_27804=[""].join("\n");
var outline_f27_9_27804=null;
var title_f27_9_27805="Smoking in pulm histiocytosis X";
var content_f27_9_27805=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57136&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57136&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Proposed pathogenetic role of smoking in pulmonary Langerhans cell histiocytosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 235px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Proposed pathogenetic scheme showing how cigarette smoke-induced neuroendocrine cell hyperplasia may contribute to airway infiltration by mononuclear phagocytes and fibrosis in pulmonary Langerhans cell histiocytosis. The degree of neuroendocrine cell hyperplasia demonstrated in this condition does not occur in most smokers without this disease. Presumably, patients with pulmonary Langerhans cell histiocytosis are either innately more susceptible to cigarette smoke or are exposed to other stimuli which interact synergistically to induce neuroendocrine cell hyperplasia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Aguayo, SM, King TE Jr, Waldron, JA Jr, et al, J Clin Invest 1990; 86:838.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_9_27805=[""].join("\n");
var outline_f27_9_27805=null;
var title_f27_9_27806="Vent responses to hypoxia";
var content_f27_9_27806=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F60134&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F60134&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 550px\">",
"   <div class=\"ttl\">",
"    Ventilatory responses to hypoxia in patients with mild and severe hypothyroidism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 530px; height: 336px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The ventilatory responses are shown as the relationships between alveolar oxygen tension (PAO2) and minute ventilation (VE, standard temperature and pressure dry [STPD]).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Zwillich AA, Pierson DJ, Hofeldt FD. Ventilatory control in myxedema and hypothyroidism. N Engl J Med 1975; 292:662.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_9_27806=[""].join("\n");
var outline_f27_9_27806=null;
var title_f27_9_27807="Contents: Renal failure";
var content_f27_9_27807=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?0/41/670\">",
"       Nephrology and Hypertension",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Renal failure",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Renal failure",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Acute tubular necrosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/6/22632\">",
"           Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/0/15369\">",
"           Crush-related acute kidney injury (acute renal failure)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/49/42773\">",
"           Definition of acute kidney injury (acute renal failure)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/54/12138\">",
"           Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/17/8472\">",
"           Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/1/34839\">",
"           Investigational biomarkers and the evaluation of acute tubular necrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/28/2501\">",
"           Nonoliguric versus oliguric acute tubular necrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/45/30425\">",
"           Overview of the management of acute kidney injury (acute renal failure)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/4/4170\">",
"           Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/10/42154\">",
"           Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/21/21847\">",
"           Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/28/4553\">",
"           Renal and patient outcomes after acute tubular necrosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Complications of renal failure",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/45/20185\">",
"           Biology of vascular calcification in renal failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/43/28343\">",
"           Bone biopsy and the diagnosis of renal osteodystrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/42/15017\">",
"           Calciphylaxis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/43/18102\">",
"           Carbohydrate and insulin metabolism in chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/31/34298\">",
"           Chronic kidney disease and coronary heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/53/16211\">",
"           Cortisol metabolism in chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/6/6248\">",
"           Lipid abnormalities in patients with chronic kidney disease not requiring dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/24/41353\">",
"           Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/24/6533\">",
"           Pericarditis in renal failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/30/10727\">",
"           Platelet dysfunction in uremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/57/33690\">",
"           Treatment of hyperphosphatemia in chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/37/2643\">",
"           Uremic mononeuropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/27/14773\">",
"           Uremic polyneuropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/20/17738\">",
"           Vascular calcification in chronic kidney disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Drug induced and toxic nephropathy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/55/7032\">",
"           Acute phosphate nephropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/5/38998\">",
"           Amphotericin B nephrotoxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/8/29833\">",
"           Cisplatin nephrotoxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/36/27209\">",
"           Clinical manifestations and diagnosis of acute interstitial nephritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/30/8679\">",
"           Consolidated aminoglycoside dosing with gentamicin and tobramycin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/2/34857\">",
"           Crystal-induced acute kidney injury (acute renal failure)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/47/20215\">",
"           Manifestations of and risk factors for aminoglycoside nephrotoxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/0/24582\">",
"           NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/49/6933\">",
"           Nephropathy induced by aristolochic acid (AA) containing herbs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/41/18072\">",
"           Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/13/10457\">",
"           Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/42/35498\">",
"           Prevention of contrast-induced nephropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/14/32999\">",
"           Renal toxicity of lithium",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/28/34245\">",
"           Treatment of acute interstitial nephritis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/60/25544\">",
"           Renal involvement with hantavirus infection (hemorrhagic fever with renal syndrome)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/44/33479\">",
"           Acute kidney injury (acute renal failure) in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/45/36570\">",
"           Assessment of kidney function",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/28/11719\">",
"           Cancer screening in patients with end-stage renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/12/26822\">",
"           Chapter 6G: Calcium and phosphate metabolism in renal failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/2/34857\">",
"           Crystal-induced acute kidney injury (acute renal failure)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/38/25190\">",
"           Diagnosis of urinary tract obstruction and hydronephrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/32/521\">",
"           Epidemiology of chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/17/8472\">",
"           Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/37/24154\">",
"           Inflammation in renal insufficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/36/1609\">",
"           Kidney disease following hematopoietic cell transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/2/25640\">",
"           Late referral to nephrologists of patients with chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/27/11701\">",
"           Serum cardiac enzymes in patients with renal failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/39/34418\">",
"           The significance of urinary eosinophils",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/38/36456\">",
"           Urine output and residual renal function in renal failure",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Progression of renal failure",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/57/13206\">",
"           Antihypertensive therapy and progression of chronic kidney disease: Experimental studies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/10/41130\">",
"           Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/45/2777\">",
"           Protein restriction and progression of chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/19/26938\">",
"           Secondary factors and progression of chronic kidney disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/57/13206\">",
"           Antihypertensive therapy and progression of chronic kidney disease: Experimental studies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/10/41130\">",
"           Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/40/28295\">",
"           Continuous renal replacement therapy in acute kidney injury (acute renal failure)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/32/4616\">",
"           Indications for initiation of dialysis in chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/35/37434\">",
"           Overview of the management of chronic kidney disease in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/24/41353\">",
"           Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/45/2777\">",
"           Protein restriction and progression of chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/25/44435\">",
"           Renal actions of dopamine",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/25/33174\">",
"           Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Metabolic and hemodynamic considerations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/37/4696\">",
"           Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/28/34245\">",
"           Treatment of acute interstitial nephritis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Tubulointerstitial disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/26/19878\">",
"           Balkan endemic nephropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/36/27209\">",
"           Clinical manifestations and diagnosis of acute interstitial nephritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/28/34245\">",
"           Treatment of acute interstitial nephritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/1/19481\">",
"           Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/20/3402\">",
"           Tumor lysis syndrome: Prevention and treatment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vascular disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/41/33433\">",
"           Chronic kidney disease associated with atherosclerotic renovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/13/13528\">",
"           Clinical presentation, evaluation, and treatment of renal atheroemboli",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/26/20905\">",
"           Peripheral artery disease in chronic kidney disease",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-692E9496E9-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f27_9_27807=[""].join("\n");
var outline_f27_9_27807=null;
